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 Hypoglycemia is associated with a variety of adverse behaviors including fatigue, 
confusion, social withdrawal, anhedonia and depressive-like behaviors. While these clinical 
symptoms are well characterized, the mechanisms of their cause are not understood. Here, we 
investigated how insulin-induced hypoglycemia causes social withdrawal and changes in mood. 
To investigate effects on social withdrawal, male 8-12-week-old C57BL/6J mice were injected 
intraperitoneally with saline and/or insulin (0.8 or 1.2units/kg). Insulin generated significant 
hypoglycemia with the lowest blood glucose levels of 64±4 and 48±5mg/dl for 0.8 and 
1.2units/kg of insulin, respectively. Insulin at either dose caused near total social withdrawal at 
0.75h, with full recovery not occurring until 4h (0.8units/kg) or 8h (1.2units/kg) post-insulin 
injection. Insulin also caused a marked elevation in plasma catecholamines. Basal 12h fasting 
norepinephrine (NE) and epinephrine (Epi) were 287±38 and 350±47pg/ml, respectively. Insulin 
at 0.8units/kg increased plasma NE and Epi to 994±73 and 1842±472 pg/ml, respectively. 
Administration of exogenous NE or Epi caused social withdrawal similar in magnitude to insulin. 
Importantly, administration of the β-2 adrenergic receptor agonist terbutaline also caused social 
withdrawal, while administration of the β-2 adrenergic receptor antagonist butoxamine blocked 
NE-induced social withdrawal. Finally, butoxamine blocked insulin-induced social withdrawal. 
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These data demonstrate that hypoglycemia-associated social withdrawal is dependent on 
catecholamines via a β-2 receptor-mediated pathway. 
 Next, we investigated how insulin-induced hypoglycemia causes anhedonia and 
depressive-like behavior. Saccharin preference testing 24h post hypoglycemia showed that mice 
receiving insulin (0.8 units/kg) had saccharin aversion (62% vs 90.5% of total fluid 
consumption). In addition, mice administered insulin had increased immobility in the forced 
swim test that took 48h to rectify. Insulin at 0.8units/kg increased plasma corticosterone 
(325±23pg/ml vs. 119±32pg/ml), Epi (814±254pg/ml vs. 350±40pg/ml), and NE (541±155pg/ml 
vs. 265±28pg/ml) at 24h post insulin treatment. Importantly, blocking of the adrenergic receptors 
with phentolamine, metoprolol and butoxamine, or treatment with the anti-depressants 
(fluoxetine and desipramine) ablated the insulin-induced saccharin aversion and increased 
immobility in forced swim test. Taken together, these data indicate that anhedonia and 
depressive-like behaviors are induced by hypoglycemia and those behaviors are dependent on 
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CHAPTER 1: INTRODUCTION 
1.1 Significance 
Hypoglycemia is the most common side effect of drugs used to treat diabetes. In 
humans, the normal range of fasting plasma glucose concentration is approximately 70-
110 mg/dl (3.9-6.1 mmol/L) and it is maintained within a narrow range. Glucose levels < 
55 mg/dl (3.0 mmol/L) with symptoms that are relieved promptly after the glucose level 
is raised document hypoglycemia (Braunwald, 2001). People with Type 1 Diabetes 
(T1D) suffer an average of two episodes of symptomatic hypoglycemia per week. An 
estimated 2~4 % of people with T1D die as a result of hypoglycemia each year. 
Hypoglycemia occurs to a similar degree in Type 2 Diabetes (T2D), as with T1D, 
because both require insulin treatment and develop insulin deficiency. Thus, 
hypoglycemia is called a “fact of life” for people with T1D and T2D (Braunwald, 2001).  
Symptoms of hypoglycemia may be adrenergic in origin due to epinephrine 
(Epi) release or related to neuroglycopenia (Hoffman et al., 1997; Hoffman, 2007; 
Korytkowski et al., 1998; Service, 1995; Ste Marie and Palmiter, 2003). The adrenergic 
symptoms include: tremor, pallor, rapid heart rate, palpitations and diaphoresis (Binder 
and Bendtson, 1992; Bolli, 1997; Korytkowski et al., 1998). Neuroglycopenic symptoms 
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range from fatigue, lethargy, headache, drowsiness and behavior change to seizures, 
unconsciousness and coma (Binder and Bendtson, 1992).  
In addition to those physical symptoms, psychological symptoms are reported. In 
a study of hypoglycemic patients, Gyland (1953) reported several symptoms of 
depression occurring in 77% of the patients and worrying and anxiety in 62% of the 
patients (Gyland, 1953). More recently, positron emission tomography (PET) scans have 
verified that glucose metabolism is often reduced in the brains of patients suffering from 
depression (Kennedy et al., 2001).  
 Although hypoglycemia and its component syndromes are well-characterized 
clinically as explained above, the mechanisms underlying these conditions remain largely 
unknown (Cryer, 2004). Herein, we investigated the mechanism underlying 
hypoglycemia-induced sickness behavior and depression. The main objectives of this 
proposal were to: 1) investigate how insulin-induced hypoglycemia causes social 
withdrawal, and 2) determine how hypoglycemia causes depressive-like behavior and 
anhedonia. 
The scope of this research proposal was to study the impact of hypoglycemia on 
the physiological and psychological symptoms. It is important to the field of 
psychoneuroimmunology to determine the mechanisms by which low blood glucose 
 2
influences activation of the adrenergic system and subsequent biobehaviors and mood 
disorders. This project is rooted in the inherent idea as well as scientific evidence 
suggesting that low blood sugar affects the adrenergic system, more specifically, 
endogenous NE and Epi that are known mediators of social withdrawal and depression.  
1.2 Objectives 
The objective of this work was to characterize the possible mechanisms of 
behavior and mood changes induced by hypoglycemia. The hypothesis of this 
dissertation is that insulin-induced hypoglycemia causes social withdrawal and 
depressive-like behaviors mediated by neuroendocrine mechanisms.  
Therefore, the first objective of this dissertation was to determine how insulin-
induced hypoglycemia causes social withdrawal. This included the following questions: 
1) is insulin-induced hypoglycemia associated with social withdrawal?; 2) do 
catecholamines cause social withdrawal?; 3) does β-2 adrenergic receptor stimulation 
cause social withdrawal?; and 4) does β-2 adrenergic receptor antagonism prevent 
insulin-induced social withdrawal? 
 The second objective of this dissertation was to investigate how insulin-induced 
hypoglycemia causes depressive-like behavior and anhedonia. To answer this question, 
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we were interested in determining if insulin-induced hypoglycemia associated with 
depressive-like behavior and anhedonia. The subsequent question then became: what is 
the mechanism and how can we possibly reverse the adverse behaviors? Further studies 
were conducted to answer: 1) does an increase in catecholamines mediate depressive-like 
behavior in insulin-induced hypoglycemia? ?; 2) do exogenous catecholamines cause 
depressive-like behavior?; 3) do exogenous catecholamines induce anhedonia?; 4) are 
adrenergic receptors associated with depressive-like behavior and anhedonia?; and 5) 





CHAPTER 2: LITERATURE REVIEW 
2.1 Type 1 Diabetes (T1D) 
 Interactions of genetic, environmental, and immunologic factors that ultimately 
lead to the destruction of the pancreatic β cells and insulin deficiency are the underlying 
cause of T1D. Ultimately, autoimmune β cell destruction occurs and most, but not all, 
individuals with T1D have evidence of islet-directed autoimmunity. However, some 
individuals who have the clinical phenotype of T1D lack immunologic markers 
indicative of an autoimmune process involving the β cells. These individuals are thought 
to develop insulin deficiency by unknown, non-immune mechanisms (Braunwald, 2001). 
 Pathologically, the pancreatic islets are infiltrated with lymphocytes, resulting in 
insulitis. After all β cells are destroyed, the inflammatory process abates, the islets 
become atrophic, and most immunologic markers disappear. Β cells seem to be 
particularly susceptible to the toxic effect of some cytokines, such as tumor necrosis 
factor-α (TNF-α), interferon-γ (IFN-γ), and interleukin-1 (IL-1) (Goodman et al., 2006). 
The precise mechanisms of β cell death are not known but may involve formation of 
nitric oxide metabolites, apoptosis and direct CD8+ T cell cytotoxicity. The islet 
destruction is mediated by T-lymphocytes, rather than islet autoantibodies, as these 
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antibodies do not generally react with the cell surface of islet cells and are not capable of 
transferring diabetes to animals (Goodman et al., 2006). 
 Numerous environmental events have been proposed to trigger the autoimmune 
process in genetically susceptible individuals; however, none have been conclusively 
linked to diabetes. Putative environmental triggers include viruses (coxsackie and rubella 
most prominently), bovine milk proteins and nitrosourea compounds. 
 
2.2 Type 2 Diabetes (T2D) 
 Type 2 diabetes affects more than 150 million people worldwide (Matthaei et al., 
2000) and is projected to increase to 300 million by the year 2020 (Crook, 2004). Unlike 
T1D, which is characterized by an absolute lack of insulin, T2D is characterized by 
defective insulin function which progresses from subclinical impaired glucose 
intolerance and insulin resistance to overt diabetes over the course of years (Zimmet et 
al., 2001). Importantly, during this subclinical phase of the disease, health complications 
such as atherosclerosis and low grade chronic inflammation are already present (Zimmet 
and Alberti, 1997). Inflammation is classically defined by four symptoms: swelling, 
redness, pain and heat. In 1941, Menkin conducted a series of simple, but elegant, 
experiments that established a firm link between diabetes and inflammation. He found 
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that pancreactomized dogs injected with an irritant into the pleural cavity showed a 
nearly 85% increase in blood glucose accompanied by proteolysis, enhanced 
gluconeogenesis and infiltration with vacuolized polymorphonuclear cells. Non-diabetic 
dogs showed no change in blood glucose and normal leukocytes after injection of the 
irritant (Menkin, 1941). Importantly, Menkin was able to block this inflammatory 
reaction by administration of insulin (Crook, 2004). These findings illustrate that 
inflammation enhances the severity of diabetes and that diabetes enhances inflammation.  
 Since this initial finding, thousands of studies have improved our understanding 
of the interaction between diabetes and inflammation. A decade ago, Pickup and 
colleagues suggested that T2D was a proinflammatory disease involving activation of the 
innate immune system (Pickup and Crook, 1998; Pickup, 2004). In support of this 
concept, subjects with T2D often have elevated serum concentration of acute-phase 
reactants, including sialic acid, α-1 acid glycoprotein, amyloid A, IL-1β, TNF-α, IL-6, C-
reactive protein and cortisol (Menkin, 1941; Zimmet and Alberti, 1997).  
Additional studies have shown that altered innate immunity and chronic 
inflammation appeared strongly associated with insulin resistance in obesity. Uysal et al. 
(1997) reported that the proinflammatory cytokine TNF-α was synthesized by adipocytes 
and was a mediator of insulin resistance in obesity. Furthermore, Tilg and colleagues 
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demonstrated that inactivation of IKK-β prevented fat-induced insulin resistance in (Tilg 
and Moschen, 2008) skeletal muscle, suggesting it as a potential therapeutic target for 
T2D. In support of this concept, NF-κB activation and proinflammatory cytokine 
production (including IL-6, IL-1 and TNF-α) were shown to be increased in the liver by 
obesity and high-fat diet, leading to insulin resistance and hyperglycemia (Cai et al., 
2005). A study by Solinas and coworkers (2007) showed that inflammation, but not 
obesity per se, triggered insulin resistance. In mice, high-fat diet-induced insulin 
resistance could be prevented through blocking an inflammatory pathway in 
macrophages by JNK1 deletion (Solinas et al., 2007). These results suggest that obesity-
induced inflammation increases high-fat diet-induced insulin resistance as well as 
resultant T2D.  
Recent data have shown that increased levels of inflammatory cytokines, such as 
IL-6 and high-sensitivity C-reactive protein (hsCRP), were linked to an elevated risk of 
clinical diabetes (Cai et al., 2005). Work by Solinas’s group indicated that the enhanced 
proinflammatory phenotype in T2D not only affected complications like cardiovascular 
disease (Solinas et al., 2007) but also exacerbated other pathologies such as depression 
and social withdrawal induced by activation of the innate immune system with 
lipopolysaccharide (Liu et al., 2007; Pradhan et al., 2001; Pradhan et al., 2001) or 
 8
hypoxia (Pradhan et al., 2001). 
 In addition to elevation of proinflammatory cytokines, T2D may be associated 
with a less effective anti-inflammatory response. The process of insulin resistance has 
been an area of prolific study. There are several factors that can lead to insulin resistance 
including increased degradation of the receptors by the proteasome, alteration of 
downstream signaling partners and phosphorylation at inhibitory serine and threonine 
residues (Pradhan et al., 2003). One of the critical regulators of this process is a class of 
molecules called suppressor of cytokine signaling (SOCS). Interestingly, several anti-
inflammatory cytokines including insulin-like growth factor-1 (IGF-1), IL-4 and IL-10 
share key signaling components with the insulin receptor and are susceptible to similar 
resistance mechanisms. 
  
2.3 The implication of proinflammatory cytokines in type 2 diabetes1
 
Introduction 
 The incidence of T2D is rapidly expanding. Some of the more obvious 
                                            
1 Guest, C. B., Park, M. J., Johnson, D. R., & Freund, G. G. (2008). The implication of proinflammatory 
cytokines in type 2 diabetes. Frontiers in Bioscience : A Journal and Virtual Library, 13, 5187-5194. 
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pathologies associated with it include: defective glucose metabolism, obesity, 
cardiovascular disease and an inability to mount an effective immune response to 
infection by certain pathogenic organisms, leading to sepsis and death. A common tie 
linking these seemingly disparate complications is chronic inflammation. Today we 
know that inflammation is regulated locally and systemically by numerous biochemical 
signals. One of the most important of these signals is a class of molecules called 
cytokines. Cytokines can be generally classified as proinflammatory or anti-
inflammatory and allow an organism to respond rapidly to an immune challenge by 
coordinating an appropriate immune response. In T2D, the balance between 
proinflammatory and anti-inflammatory cytokines is shifted toward proinflammation, 
potentially causing or exacerbating the health complications found in T2D. Over-
nutrition has been shown to trigger the innate immune system but activation of the innate 
immune system, itself, induces hyperglycemia and insulin resistance. In all likelihood, 
diabetes and chronic inflammation are inseparable and act as a reciprocal feed-forward 
loop. 
 
Proinflammatory Cytokines  
 There are a variety of cytokines labeled as proinflammatory. Almost all immune 
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cells as well as epithelial cells and adipocytes produce a subset of these cytokines. 
Generally, proinflammatory cytokines are important for initiating the innate immune 
response and for directing the subsequent adaptive immune response. The most studied 
contributors to the chronic inflammation seen in T2D are leptin, TNF-α, IL-1β and IL-6. 
 
 Leptin 
 Leptin was first discovered after a series of parabiosis experiments (Coleman, 
1973). Coleman infused the plasma of obese, hyper-leptinemic db/db mice into wild-type 
mice. Surprisingly, the mice became anorexic and died of starvation. Zhang et al. cloned 
the gene encoding the 16 kDa leptin protein (Zhang et al., 1994), while the gene 
encoding the principal leptin receptor was identified by Leiter et al.(Leiter et al., 1980). 
The crystal structure of leptin revealed a four-helix bundle similar to that of IL-6 (Zhang 
et al., 1997). The action of leptin is primarily mediated through Janus kinase-2 (JAK-2) 
and signal transducer and activator of transcription-3 (STAT-3). Targeted disruption of 
STAT-3 in the central nervous system induces a phenotype similar to mice lacking either 
leptin or the leptin receptor (i.e. obesity, diabetes and infertility) (Gao et al., 2004). 
Importantly, leptin has also been shown to act on pathways that include those containing 
insulin receptor substrate (IRS), phosphotidylinositide 3’-kinase (PI3K), mitogen 
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activated protein kinase (MAPK) (Martin-Romero and Sanchez-Margalet, 2001) and, 
recently, AMP-activated protein kinase (Minokoshi et al., 2002) (for a complete review 
see (Fruhbeck, 2006). 
Leptin is a multifunctional cytokine. It is secreted primarily by adipose tissue but 
many other tissues can produce it, including macrophages. Leptin is best known as a 
regulator of satiety and energy homeostasis (Friedman and Halaas, 1998). It acts as a 
permissive signal when energy levels are high, as represented by adequate fat stores. 
However, when energy stores are low, leptin secretion decreases and the orexigenic 
system is activated in the hypothalamus, causing feelings of hunger (Friedman and 
Halaas, 1998). Human studies that attempted to reduce food intake by exogenous 
administration of leptin have been disappointing (Heymsfield et al., 1999). A number of 
theories were raised to explain this lack of appetite suppression. One theory is that leptin 
receptors are highly expressed in the satiety centers of the hypothalamus, but in order to 
bind to these receptors, circulating leptin must pass through the blood brain barrier via a 
saturable process (Lee et al., 1996). It is possible that the high circulating leptin levels 
observed in obese individuals do not result in a similar increase in brain leptin. 
Interestingly, Faouzi et al. have shown that specific hypothalamic regions establish a 
direct contact with the general circulation and thereby display differential patterns of 
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leptin uptake and responsiveness (Faouzi et al., 2007). Another mechanism potentially 
explaining the lack of therapeutic benefits of leptin is that individuals may acquire leptin 
resistance (Van Heek et al., 1997) in a manner similar to insulin resistance, including the 
disruption of downstream leptin receptor signaling by SOCS proteins (O'Connor et al., 
2009). 
Leptin has a number of important functions in immunity. It has been shown to 
induce the production of TNF-α, IL-1β, IL-1RA, IL-R2 and IL-6 as well as that of 
reactive oxygen species, and to increase phagocytosis in some antigen presenting cells 
(Dreyer et al., 2003; Gabay et al., 2001; Lam and Lu, 2007). Recently, a role of leptin in 
the regulation of emotions and depression has been suggested. db/db mice lacking a 
functional long form of the leptin receptor showed delayed recovery from LPS- or 
hypoxia-induced social withdrawal (Johnson et al., 2007; O'Connor et al., 2005). This 
delayed recovery was accompanied by a failure to upregulate the anti-inflammatory 
cytokines IL-1RA and IL-1R2. Administration of exogenous leptin was also found to 
relieve anhedonia, demonstrating its potential to act as an antidepressant (Lu et al., 2006). 
Given these numerous functions of leptin, it is likely that its implication in T2D will be 




 TNF-α is now recognized as an important modulator of immunity and 
metabolism, inducing loss of social exploration (Bluthe et al., 2000a), production of 
acute phase proteins (Gresser et al., 1987) and activation of dendritic cell migration 
(Cumberbatch and Kimber, 1995). TNF-α is a 27 kDa protein that is processed into a 17 
kDa active form. TNF-α has been shown to induce insulin resistance (Hotamisligil et al., 
1996; Pickup and Crook, 1998) and to be implicated in the progression of obesity 
(Spiegelman and Hotamisligil, 1993). Chronic exposure of adipocytes to TNF-α strongly 
inhibited insulin-stimulated glucose uptake and decreased the phosphorylation of the 
insulin receptor by insulin (Hotamisligil et al., 1994a; Hotamisligil et al., 1994b). Some 
controversy exists as to whether TNF-α is a causative agent in T2D. In subjects suffering 
from impaired glucose tolerance (IGT), TNF-α levels were not elevated by contrast with 
IL-6 levels (Muller et al., 2002). However, TNF-α receptor knockout mice showed an 
improved glucose tolerance and increased insulin sensitivity (Hotamisligil et al., 1996). 
Leptin deficient ob/ob mice with an added p75 TNF-α receptor knockout exhibited 
improved glucose tolerance (Voros et al., 2004). Additionally, TNF-α is strongly linked 
with cardiovascular complications which are the leading cause of death in diabetes 
(Kleinman et al., 1988). TNF-α may accelerate the atherosclerotic process (Lopes-Virella 
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and Virella, 1996) through an increase in the expression of endothelin-1 (Klemm et al., 
1995) and by an alteration of lipid metabolism (Uysal et al., 1997).  
  
 IL-1β 
 Interleukin-1β is a 17.4 kDa protein derived from the cleavage of a 33 kDa 
inactive precursor by interleukin-1-β-converting enzyme (Cerretti et al., 1992). IL-1β 
signaling occurs through the evolutionarily conserved MyD88 pathway and the 
activation of NF-κB. IL-1β is produced by a variety of tissues and cell types including 
macrophages, neurons, β cells of the pancreas and adipose tissue. IL-1β is known to 
induce sickness behavior, fever and the secretion of other cytokines (Bluthe et al., 1997). 
Like TNF-α and leptin, IL-1β has important effects on metabolism. For instance, the 
activation of IL-1β receptors in hypothalamic neurons caused a marked reduction in food 
intake (Bluthe et al., 1997; Plata-Salaman, 1994). The functions of IL-1β are counter-
regulated in part by competitive inhibition by IL-1RA and IL-1R2 (Bluthe et al., 1992). 
Importantly, these counter-regulatory mechanisms were deficient in type 2 diabetic db/db 
mice injected with LPS, IL-1β or in hypoxic conditions (Johnson et al., 2007; O'Connor 
et al., 2005), in contrast with T2D humans who tend to have higher basal serum levels of 
IL-1RA. Additionally, IL-1β was shown to induce apoptosis in pancreatic β cells. This 
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finding was first described in T1D but it was also demonstrated that β cell loss in T2D 
was partially mediated by IL-1β (Bendtzen et al., 1986). 
 
 IL-6 
 IL-6 is a 27 kDa four helix-bundle cytokine with structural similarity to leptin 
(Somers et al., 1997). The IL-6 receptor is a heterodimer consisting of a gp130 subunit 
and IL-6R. IL-6 directly affects many tissues including B cells, T cells, megakaryocytes, 
macrophages, hepatocytes, osteoclasts, blood vessels, heart muscle, neuronal cells and 
the placenta (Kishimoto et al., 1995). IL-6 is produced mainly by cells of the immune 
system, skeletal muscle and the liver, but other cells types such as glia and endothelial 
cells have been reported to produce IL-6 (Kishimoto, 2005). The effects of IL-6 differ 
according to the target tissues. IL-6 is a key regulator of the acute phase response by the 
liver following infection. It induces the production of C-reactive protein, haptoglobin, 
serum amyloid A and fibrinogen (Castell et al., 1988). Like leptin, IL-6 signaling occurs 
through the MAP kinase and JAK/STAT pathways (Zhong et al., 1994). IL-6 is a potent 
endogenous pyrogen and augments LPS induced sickness behavior (Bluthe et al., 2000b). 
The role of IL-6 in T2D is complex and appears to be tissue-dependent. 
Circulating levels of IL-6 levels are increased in T2D (Pickup et al., 1997). A chronic 
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overexpression of IL-6 appears to reduce the action of insulin like growth factor in mice 
displaying growth defects. This effect was partially neutralized by the administration of 
anti-IL-6 receptor antibodies (De Benedetti et al., 1997). In addition, IL-6 has been 
shown to promote insulin resistance in hepatocytes through the activation of STAT-3 
(Senn et al., 2002). This mechanism was further elucidated by the finding that insulin 
resistance in hepatocytes was mediated by SOCS-3 and that mTOR played a critical role 
in SOCS-3 upregulation (Kim et al., 2008). Additionally, Cai et al. (2005) showed that 
T2D could be induced in mice by chronic activation of NF-κB in the liver or a high fat 
diet. These chronic inflammatory conditions induced steatosis of the liver and an 
increased production of proinflammatory cytokines by hepatocytes, including IL-6. 
Importantly, insulin resistance could be significantly improved by treatment with IL-6 
neutralizing antibodies or salicylate (Cai et al., 2005). These findings suggested a 
causative role for IL-6 in the development of T2D. However, mice with a targeted 
deletion of IL-6 developed mature-onset insulin resistance, obesity and leptin resistance 
(Wallenius et al., 2002b). It was speculated that the reason for this contrary finding was 
that the action IL-6 is tissue-dependent. Indeed, the local administration of IL-6 into the 
brains of IL-6 deficient mice partially improved the aforementioned symptoms but it had 
no effect when administered into the brain of wild type control animals (Wallenius et al., 
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2002a). The importance of tissue specificity was further emphasized by the finding that 
IL-6 enhanced insulin-stimulated glucose disposal and improved glucose metabolism in 
humans through the activation of AMPK, likely in skeletal muscle (Carey et al., 2006). 
IL-6 is clearly an important cytokine in the regulation of immunity and metabolism and it 
may be an important player in the development and complications of T2D. Further 
research will be necessary to clarify the absolute impact of IL-6 in T2D. 
 
Cytokines Resistance 
Counter-regulations are critical to maintain homeostasis. One of the most 
important mechanisms of hormone/cytokine counter-regulation is mediated by the SOCS 
family of proteins. While investigating the downstream signaling cascade of IL-6, 
Kishimoto et al. (2005) discovered a protein that they called STAT-induced STAT 
inhibitor or SSI-1. As the name indicates, this protein inhibited IL-6-mediated STAT 
activation and was itself induced by activation of STAT (Naka et al., 1997). SSI-1 was 
later found to be part of a larger family of proteins which are now entitled SOCS proteins. 
This family of proteins contains an SH-2 domain that can interact with several receptors 
at phosphotyrosine residues to block signal transduction. Some of the important signaling 
molecules regulated by the SOCS are insulin, IGF-1, leptin, IL-6, IL-4 and IL-10 (Kim et 
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al., 2008; Mooney et al., 2001; O'Connor et al., 2007). Chronic activation of the 
aforementioned receptors can induce a state of functional resistance to the ligand 
responsible for that specific receptor’s activation. In a case of ligand-dependent chronic 
activation, ligand-specific receptor insensitivity occurs, as does spillover insensitivity to 
other receptor pathways, due to SOCS upregulation. This finding has led to the 
speculation that T2D was caused by chronic over expression of SOCS proteins (Mooney 
et al., 2001). Work by our group indicated that hyperglycemia and hyperinsulinemia 
contributed to insulin resistance by activation of the nutrient sensing mTOR pathway 
(Hartman et al., 2004). Kim and colleagues extended this finding by showing that 
inhibition of mTOR by rapamycin blocked IL-6-induced SOCS protein-mediated insulin 
resistance (Kim et al., 2008). Recently, it was demonstrated that T2D-dependent 
upregulation of SOCS proteins negatively impacted the efficacy of the anti-inflammatory 
cytokine IL-4 to induce IL-1RA by (O'Connor et al., 2007), adding to the growing body 
of evidence that implicates the SOCS proteins as key immune and metabolic regulators. 
Additionally, there now appears a direct mechanistic path to explain how dysregulation 





 The treatment of diabetes was very limited until the discovery and purification of 
insulin by Banting and Best in 1921. However, before the discovery of insulin, Ebstein 
showed that daily consumption of high doses of salicylates greatly reduced glucose 
elimination in the urine (Ebstein, 2002). There were a handful of additional studies that 
explored this finding further, as reviewed by Shoelson (Shoelson et al., 2006), but these 
early promising results were overshadowed by the tremendous success of insulin in the 
treatment of hyperglycemia. Recently, the emergence of the idea that T2D is an 
inflammatory disease has led to reexamining the use of anti-inflammatory agents in the 
treatment of T2D complications. Interestingly, some of the medications currently used as 
anti-hyperglycemic agents, such as the PPARγ agonist rosiglitazone, may actually 
mediate at least part of their action through anti-inflammatory effects (Mohanty et al., 
2004). Likewise, HMG-CoA reductase inhibitors (statins) have long been known to 
reduce cardiovascular disease, a serious complication of T2D, by reducing endogenous 
cholesterol production. Recently, a growing body of evidence suggests that statins exert 
potent anti-inflammatory effects (Ridker et al., 2001). Metformin, one of the most 
commonly prescribed drugs in the treatment of T2D has been shown to act as an anti-
inflammatory agent by activating AMPK (Hattori et al., 2006). Use of metformin is 
 20
interesting because AMPK is a key local and systemic metabolic regulator. In addition, 
these findings underscore the degree of integration between metabolism and immunity. 
Finally and very recently, IL-1RA has shown promise in improving glycemia, β-cell 
secretory function and reducing markers of systemic inflammation (Larsen et al., 2007). 
By expanding our understanding of T2D, we have increased the therapeutic options 
available to the individual with diabetes, and have, in some ways, returned to Ebstein’s 




 Inflammation can be viewed as a homeostatic model with pro- and anti- 
inflammatory aspects. Proinflammatory cytokines are necessary in order to mount an 
initial effective immune response. However, this proinflammatory reaction must be 
balanced by an appropriate anti-inflammatory rejoinder in order to effectively direct the 
adaptive immune response and to avoid excessive damage to healthy tissues. 
Furthermore, the immune response must be in balance with the metabolic supplies of the 
organism. Immune and metabolic pathways are deeply intertwined and require 
synchronicity in order to promote organismal survival ((Guest et al., 2006). T2D is a key 
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example of what happens when balance goes awry. Neither cytokine nor hormonal 
networks function in isolation so it is likely that many important future contributions to 
our understanding of T2D will be found by examining the complicated interaction and 
temporal variations of immune/metabolic balance. While tremendous strides have been 
made in understanding the nature of T2D and its complications, much more work needs 
to be done to improve the lives of these individuals living with the all too familiar quartet 
of swelling, redness, pain and heat. 
 
2.4 Intensive Insulin Therapy 
 Intensive insulin therapy (IIT) differs from conventional insulin replacement in 
that it requires close monitoring of blood glucose and more frequent administration of 
insulin. This type of treatment, which includes the use of insulin pumps or basal-bolus 
injections, mimics natural insulin secretion patterns and is more effective in maintaining 
euglycemia than is conventional treatment. However, use of IIT significantly increases 
the risk of hypoglycemia. Hypoglycemia can lead to recurrent physical and psychosocial 
morbidity, and sometimes death (Cryer, 2004). IIT has been the standard care for T1D for 
more than a decade. This has expanded to include the treatment of T2D, as its incidence 
and severity have increased.  
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 Hospitalized patients in medical or surgical intensive care units (ICU) often have 
high blood glucose, even if they do not have diabetes. In the past, this was generally 
viewed by physicians as a response to other conditions and not treated. However, a 2001 
study revealed that maintaining strict glycemic control through IIT reduced mortality by 
nearly 50% and significantly reduced associated morbidities such as renal failure and 
need for mechanical ventilation in ICU patients (van den Berghe et al., 2001). Glycemic 
control became widely accepted in critical care situations and likewise, the incidence of 
hypoglycemia in critically ill patients increased. There was a six-fold increase in the 
incidence of severe hypoglycemia and a five-fold increase in multiple episodes of 
hypoglycemia in patients treated with IIT (Cryer, 2006). The underlying illness in ICU 
patients, combined with their inability to consciously respond to classical 
neuroglycopenic symptoms, further increases the risk of detrimental effects or fatality 
from hypoglycemia (Cryer, 2006; Cryer, 2006). 
 There are long-term effects of hypoglycemia as well. Young children who have 
had major hypoglycemic events such as seizures scored lower on tests of IQ and 
presented a tendency to make more errors on complicated tasks later in life. In adults, 




 Hypoglycemia is the most common result of drugs used to treat diabetes. In 
humans, the normal range of fasting plasma glucose concentration is approximately 70-
110 mg/dl (3.9-6.1 mmol/L) and it is maintained within a narrow range. Glucose levels < 
55 mg/dl (3.0 mmol/L) with symptoms that are relieved promptly after the glucose level 
is raised document hypoglycemia (Braunwald, 2001). 
 The maintenance of normal plasma glucose levels is critical to survival and 
involves a network of hormones, neural signals and glucose utilization by tissues other 
than the brain. Central and peripheral sensors detect hypoglycemia and coordinate 
neuroendocrine and autonomic responses to mobilize glucose (Bolli and Fanelli, 1999). 
The primary defense against hypoglycemia is a decrease in insulin secretion and an 
increase in glucagon secretion. Secondarily, increased sympathoadrenal outflow 
stimulates secretion of catecholamine hormones (epinephrine, norepinephrine) from the 
adrenal medulla (Cryer, 2006). Catecholamines act to suppress insulin secretion, 
stimulate hepatic/renal gluconeogenesis, and inhibit peripheral glucose use (Rizza et al., 
1979). The role of the catecholamine response becomes even more important when the 
glucagon response is absent or diminished, as seen in certain clinical syndromes and 
during prolonged hypoglycemia (De Feo et al., 1991).  
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Increased sympathoadrenal outflow from the brain generates neurogenic 
(autonomic) symptoms including tremor, shaking and anxiety; and cholinergic symptoms 
such as sweating, hunger and paresthesia (Braunwald, 2001). These symptoms are 
similar to those observed in the classic sickness response to a pathogenic infection 
(Dantzer, 2009). 
 
2.6 Hypoglycemia in Diabetes 
 Hypoglycemia is most commonly caused by the treatment of diabetes. People 
with T1D suffer an average of two episodes of symptomatic hypoglycemia per week. An 
estimated 2~4 % of people with T1D die as a result of hypoglycemia each year 
(Musselman et al., 2003; Leckie et al., 2005; Frier, 2004). Hypoglycemia affects persons 
with T2D as well as those with T1D because both require insulin treatment and develop 
insulin deficiency, which is why hypoglycemia is called a fact of life for people with 
T1D and T2D (Braunwald, 2001). 
 Hypoglycemia can lead to recurrent physical and psychosocial morbidity, and 
sometimes death (Cryer, 2008; Frier, 2004; Leckie et al., 2005). Strict glycemic control is 
essential for the treatment of diabetes and in reducing morbidity and mortality in 
critically ill patients with T1D and many with T2D. It is known that use of IIT 
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significantly increases the risk of hypoglycemia (van den Berghe et al., 2001). 
Hypoglycemia is not only the major barrier but also the limiting factor to achieving 
euglycemia and its associated benefits in these populations through the use of IIT (Cryer, 
2008; Service, 1995).  
 
2.7 Hypoglycemia and Depression 
 In a study of 1200 hypoglycemic patients, Gyland found that 77% of the patients 
showed several symptoms of depression, and 62% showed worrying and anxiety (Gyland, 
1953). More recently, positron emission tomography (PET) scans have verified that 
glucose metabolism is often reduced in the brains of patients suffering from depression. 
Gold and colleagues has examined and reviewed the non-cognitive impact of insulin-
induced hypoglycemia (Gold et al., 1993; Gold et al., 1995; Gold et al., 1997). In non-
diabetic participants, they found that hypoglycemia caused mood changes including a 
reduction in hedonic tone and energetic arousal and an increase in tense arousal. They 
also noted that tense-tiredness persisted for at least 30 min after restoration of 
euglycemia (Gold et al., 1993). Tense-tiredness may be of particular relevance to T1D in 
that it is a mood where fatigue is mixed with nervousness, tension or anxiety and often 
underlies depression (Diedrich et al., 2002; Gold et al., 1995). T1D is linked to an 
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increase in mental health and mood difficulties including anxiety, depression and social 
withdrawal (Delamater AM, ; Grey et al., 1995; Lloyd et al., 2000; Lloyd et al., 2003; 
Peyrot and Rubin, 1997; Shaban et al., 2006; Steinsdottir et al., 2008). Withdrawn 
children are anxious, lonely, fail to exhibit age-appropriate interpersonal problem-solving 
skills and are deficient in social skills and social relationships (Silverstein et al., 2005). It 
is important to note that social withdrawal is a component of these behaviors including 
tense arousal, fatigue and anxiety (Goodman et al., 2006a).  
  
2.8 Adrenergic Regulation of Hypoglycemia and Depression 
 It has been reported that communication exists between adrenergic regulation 
and energy metabolism. Schwab et al. (1993; 2004) showed a significant negative 
correlation between a hypoglycemia incidence (blood glucose < 50 mg/dl) and β-2-AR 
densities on lymphocytes and β-2-AR densities were decreased in patients with 
symptomatic hypoglycemia unawareness. Hagstrom-Toft et al. (1998) showed the 
importance of β-adrenergic regulation of lipolysis in human skeletal muscle by reporting 




 The neurophysiology of depression has been studied extensively in man and in 
animal models (Dantzer et al., 2008; Dantzer, 2009; Krishnan and Nestler, 2008). Acute 
stress is associated with a variety of physiological responses including the activation of 
the hypothalamic–pituitary–adrenal axis (HPA – axis) with a concomitant peripheral 
release of adrenocorticotropic hormone (ACTH), Epi and cortisol, a significant increase 
in centrally-controlled peripheral sympathetic nervous system tone, and the activation of 
a variety of neurochemical systems in the CNS. One of the most critical of these systems 
is the noradrenergic nucleus in the locus coeruleus (LC) (Usdin et al., 1976). This region 
controls noradrenergic tone and activity throughout the midbrain and in important 
forebrain areas including the cortex (Usdin et al., 1976). The LC has been shown to be 
critical in many regulatory functions including the regulation of affect, irritability, 
locomotion, arousal, attention and startle. Chronic stress such as footshock or handling 
results in altered β and α2-adrenergic receptor functioning (decreased α2 receptors and 
the less efficient coupling of β and α2 receptors to adenylate cyclase) in many brain 
regions (Kaan et al., 1996). These changes are thought to reflect homeostatic changes 
resulting from the increased activity of the adrenergic and noradrenergic systems 
mediating the CNS stress response. Adrenergic and noradrenergic systems and their 
receptors are involved in the mediation and recovery from the observed behavioral 
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changes following inescapable shock (Ferguson, 1978). It is of interest to note that under 
certain conditions tricyclic antidepressant medications attenuate the effects of 
inescapable shock in animals (Kitada et al., 1981; Petty and Sherman, 1980; Sherman et 
al., 1979; Sherman and Petty, 1980). 
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CHAPTER 3: BLOCKING OF β-2 ADRENERGIC RECEPTORS HASTENS 
RECOVERY FROM HYPOGLYCEMIA-ASSOCIATED SOCIAL 
WITHDRAWAL2
3.1 Abstract 
Objective: Hypoglycemia is associated with a variety of adverse behaviors 
including fatigue, confusion and social withdrawal. While these clinical symptoms are 
well characterized, the mechanism of their cause is not understood. Herein, we 
investigated how insulin-induced hypoglycemia causes social withdrawal. 
Research design and methods: Male 8-12-week-old C57BL/6J mice were 
injected intraperitoneally (IP) with or without and/or insulin, norepinephrine (NE) and 
epinephrine (Epi), terbutaline and butoxamine with subsequent measurement of blood 
glucose, social withdrawal and plasma catecholamines. 
Results: Insulin generated significant hypoglycemia with blood glucose nadirs at 
0.75h post-injection of 64 ± 4 and 48 ± 5 mg/dl for 0.8 and 1.2 units/kg of insulin, 
respectively. Insulin (0.8 or 1.2 units/kg) caused near total social withdrawal at 0.75h 
                                            
2 Park, M. J., Guest, C. B., Barnes, M. B., Martin, J., Ahmad, U., York, J. M., et al. (2008). Blocking of β-2 
adrenergic receptors hastens recovery from hypoglycemia-associated social withdrawal. 
Psychoneuroendocrinology, 33(10), 1411-1418 
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with full recovery not occurring until 4h (0.8 units/kg) or 8h (1.2 units/kg) post-insulin 
injection. Insulin also caused a marked elevation in plasma catecholamines. Basal 12h 
fasting NE and Epi were 287 ± 38 and 350 ± 47 pg/ml, respectively. Insulin at 0.8 
units/kg increased plasma NE and Epi to 994 ± 73 and 1842 ± 473 pg/ml, respectively. 
Administration of exogenous NE or Epi caused social withdrawal similar in magnitude to 
insulin. Importantly, administration of the β-2 adrenergic receptor agonist terbutaline also 
caused social withdrawal while administration of the β-2 adrenergic receptor antagonist 
butoxamine blocked NE-induced social withdrawal. Finally, butoxamine blocked insulin-
induced social withdrawal.  
Conclusions: These data demonstrate that hypoglycemia-associated social 
withdrawal is dependent on catecholamines via a β-2 receptor-mediated pathway. 
 
3.2 Introduction 
Hypoglycemia (defined as blood glucose less than 60 mg/dl) is the most 
common complication of type 1 diabetes (T1D) in childhood (Daneman, 2006; Shalitin 
and Phillip, 2007). It occurs when the administered dose of insulin exceeds the insulin 
requirement and is especially common in tightly controlled patients (Shalitin and Phillip, 
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2007). Symptoms of hypoglycemia may be adrenergic in origin due to Epi release or 
related to neuroglycopenia (Hoffman et al., 1997; Hoffman, 2007; Korytkowski et al., 
1998; Service, 1995; Ste Marie and Palmiter, 2003). The adrenergic symptoms include: 
tremor, pallor, rapid heart rate, palpitations and diaphoresis (Binder and Bendtson, 1992; 
Bolli, 1997; Korytkowski et al., 1998). Neuroglycopenic symptoms range from fatigue, 
lethargy, headache, drowsiness and behavior change to seizures, unconsciousness and 
coma (Binder and Bendtson, 1992; Hoffman, 2007). Symptoms of hypoglycemia are 
classified as mild, moderate or severe (Hoffman, 2007). Mild hypoglycemia is associated 
with adrenergic symptoms and mild neuroglycopenic symptoms such as headache and 
behavior change (Frier, 2004; Hoffman, 2007). In addition, mild symptoms are generally 
recognized by the patient and can be adequately treated without the intervention of a 
second person (Frier, 2004). Moderate and severe cases require a second person’s 
assistance (Davis et al., 1998; Frier, 2004).  
The brain is highly glucose-dependent, but it can neither synthesize glucose nor 
store significant amounts of it (Rao et al., 2006). With the more frequent use of intensive 
therapies for T1D, symptomatic hypoglycemia has increased in incidence with more than 
17% of individuals noting a hypoglycemic episode during a year’s treatment time 
(Feingold, 1991). Severe hypoglycemia, particularly that presenting with seizure or coma, 
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may result in permanent impairment especially in children less than 5 years of age (Cryer, 
2008). In addition, repeated episodes of hypoglycemia can negatively impact brain 
development and learning (Cryer, 2008). Even isolated acute episodes of mild 
hypoglycemia can transiently impair attention, mentation and memory (Northam et al., 
2001). 
Type 1 diabetes is, also, linked to an increase in mental health and mood 
difficulties including anxiety (McAulay et al., 2006), depression (Hislop et al., 2008) and 
social withdrawal (Delamater AM,). Withdrawn children are anxious, lonely, fail to 
exhibit age-appropriate interpersonal problem-solving skills and are deficient in social 
skills and social relationships (Silverstein et al., 2005). In 2000, the International Society 
of Pediatric and Adolescent Diabetes (ISPAD) Consensus Guidelines stated that 
‘‘psychosocial factors are the most important influences affecting the care and 
management of diabetes’’ and these recommendations were reiterated in the 2006/2007 
ISPAD guidelines. Unfortunately, very little is known about how T1D causes 
neurocognitive, psychosocial and behavioral difficulties and how they are regulated in 
the body either chronically or acutely. Therefore, we sought to investigate the acute 
mechanism by which insulin-induced hypoglycemia causes the adverse behavior of 
social withdrawal using a mouse model. 
 33
3.3 Materials and methods 
Materials 
All reagents and chemicals were purchased from Sigma-Aldrich (St. Louis, MO) 
except for Humalin R (insulin), which was purchased from Eli Lilly (Indianapolis, IN). 
 
Animals 
All animal care and use was conducted in accordance with the Guide for the 
Care and Use of Laboratory Animals (National Research Council). C57BL/6J mice were 
bred in-house from mice purchased from The Jackson Laboratory. Mice were group 
housed (4—8) in standard shoebox cages (17.15 cm X 28 cm) in a temperature (23.8ºC) 
and humidity (45—55%) controlled environment, with a 12-h/12-h dark/light cycle 
(0800h to 2000 h). Mice were fed pelleted food (NIH 5K52; LabDiet; Purina Mills) and 
water ad libitum. Male 8—12-week-old animals were used for all experiments. Animals 
were administered epinephrine (Epi), norepinephrine (NE) and insulin at the indicated 





Blood was collected from the tail as described previously (Hartman et al., 2004). 
Briefly, blood glucose levels were measured using a One Touch Ultra glucometer 
(Johnson & Johnson, Milpitas, CA) per the manufacturer’s instructions. In brief, mice 
were placed in a very shallow shoebox sized container (17.15 cm X 28 cm X 4 cm) such 
that the tail was exposed. The tip of the tail was then secured against the top of the 
container, snipped and blood drawn. Blood glucose was measured on the same mice 
utilized in the social withdrawal experiments. 
 
Social withdrawal 
Social withdrawal was measured as previously described (Hartman et al., 2004). 
In brief, juvenile and adult mice were individually housed for 18h prior to 
experimentation. A novel 3-4-week-old conspecific juvenile mouse (challenge mouse) 
was then confined to a 7.62 cm X 7.62 cm wire mesh enclosure (with a perforated steel 
top and bottom) which was placed in the corner of the home cage of the adult mouse (test 
mouse) for 5 min immediately prior to and at the indicated times after treatment (n = 3-4). 
A novel juvenile was supplied for each interaction at every time point. Interaction (nose 
contact) between test and challenge mouse was video-recorded. Time spent by the test 
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mouse in exploratory behavior was determined from video records. To control for 
mouse-to mouse variability in baseline activity and to allow comparison of relative 
changes in exploration levels, a pre-exposure (0 h) measurement was used as an internal 
control for each mouse. Results are expressed as percentage of baseline measurement 
and shown as means ± SEM For all behavior experiments, mice were fasted for 12h then 
pre-injected IP (where indicated) with the described agonist, antagonist or saline 0.5h 
prior to IP insulin or IP saline administration. Unrestricted access to food was provided 
0.75h after agonist or insulin administration. Social exploration was measured at the time 
points indicated with the clock starting after insulin delivery. In experiments without 
insulin, the starting point was after agonist or saline delivery. All experiments were 
performed under red light, during the dark cycle 1h into darkness. 
 
Movement 
Movement was measured in a four arm, black, Plexiglas crossmaze (arms = 27.5 
cm in length X 8 cm in width X 10 cm wall height: central platform = 8 cm X 8 cm) by 
methods previously described (Ragozzino et al., 1998). In brief, mice were placed on the 
center platform at the times indicated. Movement, as assessed by arm entries, was 
recorded over a 5 min period (from video records). The mouse was required to have all 
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four legs in the arm for an arm entry to have occurred. 
 
Plasma catecholamine analysis 
After the indicated treatments, mice were anesthetized with sodium ketamine 
hydrochloride:xylazine hydrochloride (80 mg/ml:12 mg/ml, ketamine:xylazine) at 1.5 
ml/kg body weight and blood removed from the left ventricle. Blood was collected into 
chilled heparinized centrifuge tubes and spun at 9300 X g for 8 min. Plasma was 
aspirated and stored at -80ºC. Catecholamines were determined from plasma by reverse-
phase high-performance liquid chromatography (HPLC). Solid phase extraction was with 
aluminum oxide (Bioanalytical Systems, West Lafayette, IN) and elution was in 0.2 N 
perchloric acid. Dihydroxybenzylamine was used as an internal standard to determine 
extraction efficiency. Electrochemical detection (ESA, Chelmsford, MA) utilized a 150 
X 2 mm C18 (3 mm) Hypersil column (Keystone Scientific, Bellfonte, PA) fitted with a 
2 mm C18 (3 mm) Hypersil javelin guard column (Keystone Scientific). Mobile phase 
(pH 3.0) was 75 mM NaH2PO4, 1.7 mM 1-ocatanesulfonic acid, 25 mM Na2EDTA, 7% 
(vol/vol) acetonitrile and 0.1% (vol/vol) triethylamine. The interassay coefficient of 




Data are presented as mean ± SEM and were analyzed by two- or three-way 
ANOVA depending on the experimental design with repeated measurements in the time 
factor as applicable. Post hoc comparisons of individual group means were carried out 




Insulin-induced hypoglycemia is associated with social withdrawal 
Table 3.1 demonstrates that when C57BL/6J mice were withheld food for 12h, 
blood glucose ranged from 117 ± 6 to 131 ± 11 mg/dl. When mice were injected IP with 
insulin, blood glucose fell. Blood glucose 0.75h after 0.4, 0.8 or 1.2 units/kg of insulin 
was 99 ± 14 mg/dl (p = 0.029), 64 ± 4 mg/dl (p = 0.001) or 48 ± 5 mg/dl (p = 0.0008), 
respectively compared to control (151 ± 13 mg/dl). Food was made accessible to the 
mice 0.75h post injection. At 8h post insulin injection, and 7.25h post return to 
unrestricted food access, blood glucose ranged from 189 ± 17 to 200 ± 6 mg/dl in insulin 
treated and control animals. Fig. 3.1 shows the impact of insulin administration on social 
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exploration. At 0.75h after IP insulin injection, social withdrawal was nearly complete in 
mice treated with 0.8 and 1.2 units/kg insulin, demonstrating a 91 ± 11% (p = 0.0001) 
and 96 ± 5% (p = 0.0001) loss in social exploration, respectively. Insulin delivered at 0.4 
units/kg did not impact social exploration. In addition, recovery from insulin-induced 
social withdrawal took 4 and 8h to recovery from after 0.8 and 1.2 units/kg insulin, 
respectively. Finally, arm entries into a plus maze were examined to assess mouse 
mobility after administration of 0.8 units/kg insulin. As with social withdrawal, 0.75h 
after insulin injection, arm entries in insulin-treated mice were reduced {44 ± 10 vs 14 ± 
4 (p = 0.038)}. After 3h (for arm entries), insulin-treated mice had fully recovered. Taken 
together, these findings indicate that insulin-induced hypoglycemia is associated with 
social withdrawal and loss of movement. 
 
Catecholamines cause social withdrawal 
 Fig. 3.2A demonstrates that 0.8 units/kg insulin IP induced a marked elevation in 
plasma NE and Epi. At 0.75h after insulin, NE was increased compared to control: 994 ± 
73 pg/ml vs 439 ± 50 pg/ml (p = 0.001). At 120 min after insulin, NE returned to near 
control levels: 994 ± 73 pg/ml vs 351 ± 54 pg/ml (p = 0.052). After insulin (0.75 h), Epi 
increased to 2184 ± 833 pg/ml vs 390 ± 11 pg/ml (p = 0.089) and was significantly 
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elevated at 120 min post insulin, 1842 ± 472 pg/ml vs 351 ± 144 pg/ml (p = 0.01). To 
determine the impact of catecholamines on social withdrawal, social exploration was 
examined. Fig. 3.2B shows that when NE was administered IP at 1.0, 1.5 or 2.0 mg/kg, 
social exploration was significantly curtailed 0.5h after injection {63 ± 5% (p = 0.009), 
38 ± 9% (p < 0.001) or 19 ± 3% (p < 0.001), respectively}. Recovery from NE-induced 
social withdrawal occurred at 2h for NE at 1.0 mg/kg and at 4h for NE at 1.5 and 2 
mg/kg. Fig. 3.2C demonstrates that Epi was a more potent inducer of social withdrawal. 
At 0.25, 1.0 and 1.5 mg/kg, Epi caused social exploration to fall to 44 ± 4% (p = 0.0002), 
27 ± 3% (p < 0.0001) and 24 ± 2% (p < 0.0001) of control, respectively, 0.5h after 
administration. Recovery occurred in 2, 4 and 12h after 0.25, 1.0 and 1.5 mg/kg Epi, 
respectively. Taken together, these findings indicate that catecholamines cause social 
withdrawal. 
 
β-2 adrenergic receptor stimulation causes social withdrawal which β-2 adrenergic 
receptor antagonism prevents 
 To determine if catecholamine-dependent social withdrawal was mediated by the 
β-2 adrenergic receptor, β-2 agonism was performed using the β-2 agonist terbutaline (Ito 
et al., 2006; Podojil et al., 2004; Thaker et al., 2006). Fig. 3.3A shows that when 
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terbutaline was administered IP at 5.0 mg/kg, social withdrawal occurred similar to that 
seen with 1.5 mg/kg NE (30 ± 3% vs. 35 ± 7% at 0.5 h), (43 ± 11% vs. 51 ± 14% at 2 h), 
(67 ± 7% vs. 80 ± 1% at 4 h). Importantly, when the β-2 antagonist butoxamine (Junker 
et al., 2002; Kaan et al., 1996) was administered IP at 5.0 mg/kg to mice just prior to NE 
injection (1.5 mg/kg), NE-dependent social withdrawal was completely blocked. Taken 
together, these findings indicate that catecholamine-dependent social withdrawal is 
mediated by the β-2 adrenergic receptor. 
 
Butoxamine blocks insulin-induced social withdrawal 
 Table 3.2 demonstrates that when C57BL/6J mice were withheld food for 12 h, 
blood glucose ranged from 137 ± 15 to 149 ± 17 mg/dl. When mice were injected IP with 
insulin (0.8 units/kg) or insulin (0.8 units/kg) + butoxamine (5 mg/kg), blood glucose fell 
to 67 ± 4 mg/dl (p < 0.0001) or 78 ± 6 mg/dl (p = 0.0004), respectively, compared to 
control (150 ± 10 mg/dl). At 8h post insulin injection and 7.25h post return to 
unrestricted food access, blood glucose ranged from 202 ± 13 to 231 ± 7 mg/dl in insulin 
treated and control animals. Butoxamine did not alter the hypoglycemic response to 
insulin. Fig. 3.4A shows the impact of butoxamine administration on social exploration. 
At 0.75h after IP insulin injection, social withdrawal was nearly complete demonstrating 
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a 96 ± 6% (p = 0.0007) loss in social exploration. Importantly, butoxamine completely 
blocked the effect of insulin-induced hypoglycemia on social withdrawal while the pan-α 
blocker phentoloamine and β-1 specific antagonist metoprolol did not (Fig. 3.4B). Taken 
together, these findings indicate that insulin-induced hypoglycemia-dependent social 
withdrawal is mediated by the β-2 adrenergic receptor. 
 
3.5 Discussion 
We have previously shown that in mouse models of T1D and T2D social 
withdrawal induced by innate immune activation is exaggerated and prolonged (Lin et al., 
2007). In diabetic mice administered the toll-like receptor 4 (TLR-4) agonist 
lipopolysaccharide (LPS), prolonged immune-activated social withdrawal appeared 
dependent on hyperglycemia (Lin et al., 2007). This is likely due to the impact of 
hyperglycemia on macrophages because hyperglycemia augments LPS-induced pro-
inflammatory cytokine production by macrophages via a pathway requiring p38 map 
kinase (Sherry et al., 2007). In general, social withdrawal as part of classical sickness 
symptoms is caused by innate immune activation (Dantzer, 2004) and is dependent on 
pro-inflammatory cytokines, especially TNF α and IL-1 β, and their impact in the brain 
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(Dantzer et al., 2008). 
As shown in the results for Fig. 3.1, insulin-induced hypoglycemia causes social 
withdrawal and reduced mouse movement. When insulin is administered at 1.2 units/kg, 
blood glucose nadirs at 48 mg/dl (Table 3.1) 0.75h after insulin injection, which 
corresponds with nearly complete social withdrawal. Interestingly, hypoglycemia-
associated social withdrawal took 8h to fully recover, indicating a significant behavioral 
impact of hypoglycemia extending well beyond the acute event. This phenomenon 
should not be surprising because hypoglycemia triggers a variety of bioactive 
compounds that raise blood glucose. These include catecholamines, glucagon, growth 
hormone and cortisol. Metabolically, these agents stimulate glucose production initially 
through glycogenolysis and then later through gluconeogenesis, decreased muscle 
glucose storage/oxidation and use of alternative fuels (Hoffman, 2007). Catecholamines, 
especially, are key to the early glucose rise in T1D because disease-based loss of 
pancreatic islet cells also disrupts the ability of the pancreas to produce glucagon (Brown 
et al., 2008).  
Insulin-induced hypoglycemia was also associated with decreased mouse 
movement as measured by arm entries in a cross-maze. When examined as a percentage 
(at 0.8 units/kg insulin), loss of social exploration (at 0.75 h) was greater (91%) than loss 
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of movement (68%). This indicates that loss of social exploration may not just be due to 
a simple loss of activity. In general, severe insulin-induced hypoglycemia lowers brain 
ATP stores that can take up to 3h to fully recover, if the hypoglycemia is serious enough 
to cause coma as documented by EEG (Agardh and Rosen, 1983). When insulin was 
used to drop blood glucose in diabetic humans with from ~180 mg/dl to ~40 mg/dl 
within 1 h, adrenergic symptoms as measured by pulse returned to normal 1h after the 
pulse peaked at 1h post-insulin administration (Deacon et al., 1977). Unfortunately, in 
both animals and humans, little has been reported regarding recuperation from insulin-
induced hypoglycemia and almost nothing is known about recovery from adverse 
behaviors associated with insulin-induced hypoglycemia. Most work has focused on how 
to effectively and rapidly restore blood glucose and other metabolic indicators of 
hypoglycemia and correlating return of these biomarkers to normal as resolution (Pratley 
and Salsali, 2007). Only in severe coma-inducing hypoglycemia does the brain tend to be 
examined, but in these studies behavior and behavioral recovery is ignored. 
Gold et al. (1995, 1997) have examined and reviewed the non-cognitive impact 
of insulin-induced hypoglycemia (Gold et al., 1995; Gold et al., 1997). In non-diabetic 
participants, they found that hypoglycemia caused mood changes including a reduction 
in hedonic tone and energetic arousal and an increase in tense arousal. They also noted 
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that tense-tiredness persisted for at least 30 min after restoration of euglycemia (Gold et 
al., 1993). Tense-tiredness may be of particular relevance to T1D in that it is a mood 
where fatigue is mixed with nervousness, tension or anxiety and often underlies 
depression (Goodman et al., 2006; Lustman and Clouse, 2007). It is important to note 
that social withdrawal is a component of these behaviors including tense arousal, fatigue 
and anxiety (Goodman et al., 2006). In addition, there may be a stratification of 
hypoglycemia-associated behaviors because we found that peak social withdrawal was 
more severe than peak loss of movement. 
Another question Fig. 3.1 poses is whether insulin itself, not insulin-induced 
hypoglycemia, causes the social withdrawal observed. Gold et al. (1995, 1997) found 
that the mood disturbances they observed occurred in the insulin-induced hypoglycemia 
subjects and not those exposed to hyperinsulinemic glucose clamp. In addition, we have 
shown that in a mouse model of T1D, insulin does not induce social withdrawal, but 
appears to improve social exploration in hyperglycemic mice, especially if insulin is 
administered ICV (Lin et al., 2007).We have also shown that in non-diabetic and T2D 
mice that IGF-I does not impact baseline social exploration (Johnson et al., 2005).  
Fig. 3.2A demonstrates that the insulin dose administered was significant enough 
to up-regulate plasma NE and Epi. These findings indicated that NE or Epi might be 
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responsible for the social withdrawal seen with insulin-induced hypoglycemia. As Fig. 
3.2B and C show, NE and Epi both cause social withdrawal. Interestingly, Epi appears to 
be a more potent inducer of social withdrawal, being able to cause social withdrawal at 
one quarter the dose of NE. In addition, the impact of Epi on social withdrawal was 
significantly longer lasting when both were administered at 1.5 mg/kg. Fig. 3.3 shows 
that the β-2 adrenergic receptor agonist terbutaline induces social withdrawal and that the 
β-2 receptor agonist butoxamine completely blocks NE-induced social exploration. 
Importantly, butoxamine did not raise blood glucose in response to insulin (Table 3.2), 
suggesting that insulin-induced social withdrawal is not mediated directly by 
hypoglycemia but by the impact that hypoglycemia has on catecholamines. Together 
these findings point to β-2 adrenergic stimulation as key to catecholamine-dependent 
social withdrawal. Critically, the β-2 antagonist butoxamine blocked insulin-induced 
social withdrawal (Fig. 3.4A), while the pan-α blocker, phentolamine, and the β-1 
blocker, metoprolol, did not (Fig. 3.4B). These findings strongly support our contention 
than hypoglycemia-associated social withdrawal induced by insulin is dependent on 
catecholamines via a β-2 receptor-mediated pathway. While these finding do not exclude 
glucagon and/or cortisol/corticosterone as modulators of behavior in insulin-induced 
hypoglycemia, with regard to social withdrawal, catecholamines appear paramount. 
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A key question is how NE/Epi causes social withdrawal. Both NE and Epi (as 
well as terbutaline) are rather polar compounds that do not readily enter the CNS 
(Goodman et al., 2006). In general, Epi may cause restlessness and apprehension but 
these feelings in humans are usually ascribed to the effect of Epi on the cardiovascular 
system, skeletal muscle and/or intermediary metabolism (Goodman et al., 2006). NE is 
less commonly linked to restlessness and apprehension than Epi (Goodman et al., 2006) 
and, like Epi, NE is rapidly inactivated by the same enzymes that methylate and 
oxidatively deaminate Epi (Goodman et al., 2006). In our study, the apparent reason Epi 
is a more potent inducer of social withdrawal than NE is that Epi is a more effective β-2 
adrenergic agonist than NE (Goodman et al., 2006). Support for this contention is that the 
β-2 selective adrenergic agonist terbutaline caused social withdrawal and, in general, β-2 
agonists are more likely to induce feelings of restlessness, apprehension and anxiety 
(Goodman et al., 2006). Importantly, these behaviors are linked in certain instances to 
social withdrawal (Goodman et al., 2006). The probable mechanism by which β-2 
adrenergic stimulation causes social withdrawal either due to adrenergic agents or 
insulin-induced hypoglycemia and subsequent catecholamine up-regulation is through 
‘‘stress’’-induced hypothalamic NE turnover (Anisman and Sklar, 1979; Weiss et al., 
1975) because NE turnover induces social withdrawal in immune-based sickness models 
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(Marvel et al., 2004). Finally, what causes glucoprivic triggering of noradrenergic 
neurons in the ventromedial hypothalamus is not clear (Levin, 2007), but nearly one-
third of young adults with T1D experience psychological distress and this distress 
appears linked to hypoglycemia especially in those attempting tighter glucose control 
with subcutaneous insulin infusion (Hislop et al., 2008). Therefore, the importance of 
understanding the adverse impact of hypoglycemia on behavior is significant. 
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3.6 Figures and Tables 
 
Table 3.1: Blood Glucose (mg/dl) after Insulin Injection 
 
Treatment 0 h 0.75 h 8 h 
Saline 130 ± 11 151 ± 13 196 ± 4 
Insulin 0.4 units/kg 131 ± 11 99 ± 14 * 190 ± 19 
Insulin 0.8 units/kg 117 ± 6 64 ± 4 * 200 ± 6 
Insulin 1.2 units/kg 124 ± 18 48 ± 5 * 189 ± 17 
*p<0.05, 0.75h vs. 0h. 
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Table 3.2: Plasma Glucose (mg/dl) after Insulin (Ins) and Butoxamine (BTX) 
Injection 
 
Treatment 0 h 0.75 h 8 h 
Saline 149 ± 17 150 ± 10 226 ± 17 
Butoxamine 139 ± 7 151 ± 14 202 ± 13 
Insulin 137 ± 15 67 ± 4 * 224 ± 11 
Ins + BTX 142 ± 7 78 ± 6 * 231 ± 7 



































































Fig 3.1. Insulin induces social withdrawal. After a 12h fast, C57BL/6J mice were 
administered either insulin (Insulin) or saline control (Saline) IP as indicated. Social 
exploration was measured at 0, 0.75, 2, 4 and 8h after insulin delivery. Unrestricted 
access to food was provided after the 0.75 time point. Results are expressed as 
percentages of the baseline measurement, means ± SEM; n=3, *P <0.05, **P <0.001 





























































































































































































Fig 3.2. Catecholamines cause social withdrawal. (A) After a 12h fast, C57BL/6J mice 
were administered either insulin (Insulin) or saline control (Saline) at 0.8 units/kg insulin 
IP as indicated. Plasma catecholamines were measured by HPLC at 0, 45 and 120 min 
post insulin injection. Results are expressed as mean ± SEM; n = 3, *P <0.01, **P 
<0.001 Insulin vs. Saline. (B) Mice were administered NE (IP) at the concentrations 
indicated. Social exploration was measured at 0, 0.5, 2, 4, 8 and 12h after NE delivery. 
Results are expressed as percentages of the baseline measurement, means ± SEM; n=4. 
*P<0.01, **P < 0.0001, NE vs. Saline. (C) Mice were administered Epi (IP) at the 
concentrations indicated. Social exploration was measured at 0, 0.5, 2, 4, 8 and 12h after 
Epi delivery. Results are expressed as percentages of the baseline measurement, means ± 

































































































































Fig. 3.3, continued 
Fig 3.3. β-2 adrenergic receptor stimulation causes social withdrawal which β-2 
adrenergic receptor antagonism prevents. (A) C57BL/6J mice were IP administered 
NE, terbutaline (Terb) or saline control (Saline) at the concentrations indicated. Social 
exploration was measured at 0, 0.5, 2, 4, 8 and 12h after injection. Results are expressed 
as percentages of the baseline measurement, means ± SEM; n=3, *P<0.01, **P < 0.0001, 
NE or Terb vs. Saline. (B) Mice were IP administered NE, butoxamine (Butoxamine) or 
Saline at the concentrations indicated. Social exploration was measured at 0, 0.5, 2, 4, 8 
and 12h after injection. Results are expressed as percentages of the baseline 









































































































































Fig. 3.4, continued 
Fig. 3.4. Butoxamine blocks insulin-induced social withdrawal. (A) After a 12h fast, 
C57BL/6J mice were pretreated with or without butoxamine (BTX) (5 mg/kg, IP, 
pretreatment for 30 min) as indicated. Mice were then administered insulin (Ins) (0.8 
units/kg, IP or saline control (Saline) IP as indicated. Social exploration was measured at 
0, 0.75, 2, 4 and 8h after insulin delivery. Unrestricted access to food was provided after 
the 0.75 time point. Results are expressed as percentages of the baseline measurement, 
means ± SEM; n=3, *P < 0.0001, **P = 0.0007 Insulin vs Insulin + butoxamine. (B) Like 
in A, C57BL/6J mice were pretreated with either phentolamine (Phen) (1 mg/kg, IP) or 
metoprolol (Meto) (10 mg/kg, IP), as indicated. Mice were then administered insulin (0.8 
units/kg) or saline control IP. Social exploration was measured as in A. Results are 
expressed as percentages of the baseline measurement means ± SEM; n=4-6, *p=0.0126 
**p=0.0018 ***p<0.0001 Saline vs. Insulin +/- Phen or Meto. 
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CHAPTER 4: HYPOGLYCEMIA/HYPERINSULINEMIA CAUSE  
DEPRESSIVE-LIKE BEHAVIORS IN MICE 
4.1 Abstract 
In humans, hypoglycemia is associated with a variety of mood changes including 
a reduction in hedonic tone and energetic arousal, and an increase in tense arousal. While 
these clinical symptoms are well characterized, their underlying mechanism is not. 
C57BL/6J mice were administered 0.8 units/kg insulin that generated a blood glucose 
nadir of 50 ± 2 mg/dl 0.75h after injection. At 4h post-insulin administration, blood 
glucose had returned to normal (148 ± 10 mg/dl). Saccharin preference testing 24h post-
hypoglycemia showed that insulin-receiving mice had saccharin aversion (62 % vs 91 % 
of total fluid consumption) that took 48h to resolve. In addition, insulin-treated mice had 
increased immobility in the forced swim test that took 48h to rectify. Activity, burrowing, 
elevated zero maze and novel object recognition were not impacted 24h post 
hypoglycemia. Insulin at 0.8 units/kg increased plasma epinephrine (814 ± 254 pg/ml vs. 
350 ± 40 pg/ml) and norepinephrine (541 ± 155 pg/ml vs. 265 ± 28 pg/ml) 24 h-post 
insulin treatment. Importantly, blocking adrenergic receptors or treatment with anti-
depressants ablated the behaviors of insulin-induced saccharin aversion and increased 
immobility in the forced swim test. Taken together, these data indicate that anhedonia 
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and depressive-like behavior are induced by hypoglycemia, and these behaviors are 
dependent on catecholamines in an adrenergic receptor-mediated manner.   
 
4.2 Introduction  
Hypoglycemia is the most common acute side effect in insulin-treated subjects 
with type 1 diabetes (T1D), both in children (Becker and Ryan, 2000) and adults (Frier, 
2008), and it is one of the biggest hurdles in the improvement of glycemic control (Cryer, 
1994; Cryer, 2002; Cryer, 2008; Havlin and Cryer, 1988; Nery, 2008). Many research 
studies have focused on the cognitive impact of hypoglycemia, but less research has 
investigated the psychophysiological bases of such states, including depression. Recent 
studies by Gold et al. (1995, 1997) have reported biological changes in mood during 
insulin-induced hypoglycemia. In both non-diabetic and diabetic subjects, Gold et al. 
(1995) found that acute hypoglycemia caused negative mood states including tense-
tiredness, a reduction in hedonic tone (less happy), an increase in tense arousal (more 
tense) and a decrease in energetic arousal (less energetic). A study by McCrimmon et al. 
(1995) of 16 healthy individuals exposed to insulin-induced hypoglycemia has confirmed 
and extended the findings of Gold et al (1995). The healthy individuals presented 
increased anger and became more pessimistic about their life problems in addition to a 
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reduction in hedonic tone and an increase in tense arousal. Moreover, in a study of 1200 
hypoglycemic patients, Gyland (1953) found that 3 out of 4 hypoglycemic patients 
showed symptoms of depression and 2 out of 3 patients had worrying and anxiety. More 
recently, reduced glucose metabolism in the brains of patients with depression has been 
verified by positron emission tomography (PET) scans (Baxter et al., 1989; Kumar et al., 
1993).   
Symptoms of hypoglycemia are classified into two categories: autonomic and 
neuroglycopenic. Autonomic symptoms are the result of the impaired perception of 
physiologic changes caused by autonomic nervous (sympatho-adrenal) system activation 
in response to hypoglycemia (Deary et al., 1993; Hepburn et al., 1991; Towler et al., 
1993). The stimulation of autonomic centers in the hypothalamus triggers a peripheral 
autonomic discharge, where catecholamine-mediated adrenergic symptoms comprise 
sweating, anxiety, tremulousness, palpitations and paresthesias (Diedrich et al., 2002; 
Field, 1989; Hoffman, 2007). Neuroglycopenic symptoms occur during hypoglycemia as 
a direct result of a lack of glucose requirement for brain function and are characterized 
by symptoms such as difficulty in thinking and speech, weakness, tiredness and 
sleepiness (Diedrich et al., 2002; Gold et al., 1995).  
The counter-regulatory hormonal changes in response to hypoglycemia are well 
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defined. In the normal physiological condition, hypoglycemia counter-regulation 
includes three responses: 1) secretion of norepinephrine from sympathetic postganglionic 
nerve terminals, epinephrine from the adrenal medullae and cortisol/corticosterone from 
the adrenal cortex; 2) secretion of growth hormone by the anterior pituitary gland; and 3) 
secretion of glucagon and pancreatic polypeptide from the pancreas (Diedrich et al., 
2002; Musselman et al., 2003). The acute metabolic effects of the harmonized 
neuroendocrine response involve increased glucose production and restrained glucose 
utilization through proteolysis, lipolysis, glycogenolysis and gluconeogenesis (Diedrich 
et al., 2002; Musselman et al., 2003). Studies of the relationship between depression and 
glucose metabolism have shown that patients with major depression demonstrate insulin 
resistance during insulin tolerance tests and intravenous or oral glucose tolerance tests. 
An important report from adrenalectomized subjects suggests that epinephrine has a 
pivotal role in changes in hedonic tone, tense arousal and energetic arousal (Hepburn et 
al., 1996). While control subjects showed a reduction in happiness and an increase in 
tension after acute hypoglycemia, adrenalectomized patients did not present either 
symptom (Hepburn et al., 1996). This indicates that Epi release from adrenal glands is a 
required component of tense arousal induced by hypoglycemia. 
Based on the relationship between depression and hypoglycemia, it is not 
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surprising that both have symptoms in common: nervousness, irritability, exhaustion, 
drowsiness, insomnia, constant worrying, mental confusion, rapid pulse, internal 
trembling, forgetfulness, headache and unprovoked anxieties. While these clinical 
symptoms are well characterized in humans, their underlying mechanism and 
experimental models in mice are not well established. Here we investigated the 
mechanism by which insulin-induced hypoglycemia causes depressive-like behavior and 
anhedonia in mice. 
 
4.3 Materials and methods 
Materials 
 All reagents and chemicals were purchased from Sigma-Aldrich (St. Louis, MO) 
except for Humalin R (insulin), which was purchased from Eli Lilly (Indianapolis, IN). 
 
Animals 
 All animal care and use was conducted in accordance with the Guide for the 
Care and Use of Laboratory Animals (National Research Council). C57BL/6J mice were 
bred in-house from mice purchased from The Jackson Laboratory. Mice were group 
housed (4-8) in standard shoebox cages (17.15 x 28 cm) in a temperature (23°C) and 
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humidity (45–55%) controlled environment with a 12-h/12-h dark-light cycle (0800h to 
2000 h). Mice were fed pelleted food (NIH 5K52; LabDiet; Purina Mills) and water ad 
libitum. Male 8- to 12-wk-old animals were used for all experiments. Animals were 
administered Epi and NE at the indicated concentrations via IP injection. Insulin was 
administered IP at 0.8 units/kg/mouse or ICV at 0.2 units/mouse/2 µl injection after 12 
hours of fasting when indicated. Phentolamine (1mg/kg/mouse), metoprolol 
(10mg/kg/mouse) or butoxamine (5mg/kg/mouse) were administered IP twice, 30 min 
prior to insulin injection and 30 min prior to the forced swim test (FST). Antidepressants 
fluoxetine (10 mg/kg/mouse) or desipramine (5mg/kg/mouse) were also administered IP 
30 min prior to FST. 
 
Locomotor Activity Test (LAT) 
 To estimate locomotor activity, mice were kept in their home cage and video 
recorded during 5 min tests using a camera mounted approximately 65.0 cm directly 
above the center of the cage floor. On the video records, cages were divided into four 
identical rectangles and a trained observer who was blind to experimental treatments 
determined the frequency of line crossing. A mouse was considered to have crossed a 
line only if its fore and hind limbs entered a new rectangle.  
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Forced Swim Test (FST) 
 The FST measures depressive-like behavior and was conducted as described by 
Porsolt (2000). Briefly, each mouse was placed individually in a cylinder (diameter: 16 
cm; height: 31 cm) containing 15 cm of water maintained at 25 ± 1 °C. The water was 
changed and the cylinders were cleaned thoroughly between testing sessions. Mice were 
tested for 6 min and then returned to their home cage. The duration of immobility, 
swimming and climbing was evaluated during the last 5 min of the test.  
 
Tail Suspension Test (TST) 
 The TST was carried out as previously described (Steru et al., 1985). Briefly, an 
adhesive tape was fixed to the mouse tail (distance from the tip of the tail = 2 cm) and 
hooked to a horizontal ring stand bar placed 30 cm above the floor. The test was 
conducted for a period of 10 min in a visually isolated area. The apparatus was cleaned 
thoroughly after each mouse. Mice demonstrated several escape attempts interspersed 
with immobility periods during which they hung passively and completely motionless. 
Each mouse was repeatedly tested 24 h, 48h and 72h after treatment. It has been 
previously shown that exposure to the TST can be repeated without causing any 
significant habituation (El Yacoubi et al., 2003). 
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Saccharin Preference Test (SPT) 
 The saccharin preference test measures anhedonia, pleasure avoidance, a 
fundamental characteristic of depression (Willner, 1997). Individual mice were housed in 
standard cages fitted with adapted wire tops to allow access to two fluids: water or 0.4% 
sodium saccharin solution. Prior to experimental treatment, mice were exposed to two 
bottles: one for water and another for 0.4% sodium saccharin solution, in order to 
acclimate them to the presence of two fluid sources in the cage. In order to avoid any 
place preference, the relative location (left or right) of the saccharin tube was changed 
whenever fluid intake was measured. Fluid consumption was measured by volume of 
fluids before and/or after each test session.  
 
Novel object recognition test 
To investigate a function of hippocampal-dependent working memory, mice 
were familiarized with a pair of identical objects which were located near opposite 
corners of the same end of a large shoebox cage. During the acclimation period, the 
mouse was exposed to the object for 1-6 h. Before and after the object was placed in the 
adult's cage, it was thoroughly cleaned with 70% ethanol and dried to sanitize it and 
ensure the absence of olfactory cues on the object. On the test day, 24h after the end of 
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the acclimation period, mice were re-exposed to the two familiar objects from the 
acclimation period (sample phase). Both familiar objects were placed near the opposite 
corners of the same end of a large shoebox mouse cage (fresh and clean cage). The 
mouse was then placed in the center of the cage, opposite from the objects. The mouse 
was allowed to freely explore the cage and the familiar objects for five minutes. The 
mouse was then removed from the shoebox cage and returned to its home cage, and the 
objects were removed, cleaned with 70% ethanol and dried again. The mice were then 
exposed to insulin. Immediately following treatment, mice were placed in a cage just as 
in the familiar object period, except one of the two familiar objects was replaced with a 
novel object (recall phase). The mouse was allowed to explore each of the objects for a 5 
minute period, after which the mouse was removed and replaced into its home cage. The 
recall phase was repeated at time points up to 24h post-treatment. To test for the effects 
of insulin on memory formation, the mice were first exposed to hypoxia, then given a set 
amount of time to recover (up to 24 hours), then introduced to the novel object test. 
 
Elevated zero maze 
Elevated zero maze consisted of a circular platform (6-cm width with a 40-cm 
inner diameter) that was equally divided into four quadrants. Two quadrants on opposite 
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sides of the platform were enclosed by walls (14 cm high); the other two quadrants were 
open and bordered by a lip (0.3 cm high). The maze was elevated 72 cm above the floor. 
The mouse was placed just inside a closed arm with all four paws inside and its nose 
pointing inside the closed arm. The mouse was observed and video-recorded for 5 
minutes then replaced in its home cage. The maze was cleaned with 75% ethanol 
between runs. Mice were monitored in real-time while they were being video-recorded.  
 
Burrowing test 
Burrowing tubes were constructed from a 2 inch diameter polyvinyl chloride 
(PVC) conduit. Sections of pipe were cut to 200mm in length, and included an end cap 
on one end. At the open end of the tube, two small bolts were inserted to prop up the tube, 
and fastened in place with a nut, with the threading coated in nylon, to prevent loosening. 
The end product was an open ended (one end only) tube approximately 200 mm in length, 
with the open end propped up approximately 60 mm. For acclimation, baseline and 
experimental treatment evaluation of burrowing activity, the mice received their 
respective treatment (no treatment for acclimation or baseline), and the burrowing tube 
was placed in the corner of a large conventional mouse cage. Pelleted food (100-200 g) 
was placed on the floor of the burrowing tube. During the first 6 hours after initial 
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placement of the burrowing tube in the cage, the amount of food displaced by the 
mouse’s burrowing activity was measured and refilled (to avoid a ceiling effect) at 1h 
intervals. At the end of the 12 hour testing period, the amount of food displaced from the 
tube was measured and the tube and its contents were removed from the home cage. 
 
Blood Glucose 
 Blood was collected from the tail blood as we described previously (Hartman et 
al., 2004). Briefly, blood glucose levels were measured using a One Touch Ultra 
glucometer (Johnson & Johnson, Milpitas, CA) per the manufacturer’s instructions. In 
brief, mice were placed in a very shallow shoebox sized container (17.15 x 28 x 4 cm) 
such that the tail was exposed. The tip of the tail was then secured against the top of the 
container, snipped and blood drawn. Blood glucose was measured on the same mice 
utilized in the behavioral experiments. 
 
Plasma Catecholamine Analysis 
 After the indicated treatments, mice were anesthetized with sodium ketamine 
hydrochloride:xylazine hydrochloride (80 mg/ml:12 mg/ml, ketamine:xylazine) at 1.5 
ml/kg body weight and blood removed from the left ventricle. Blood was collected into 
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chilled heparinized centrifuge tubes and spun at 9300 x G for 8 min. Plasma was 
aspirated and stored at -80o C. Catecholamines were determined from plasma by reverse-
phase high performance liquid chromatography (HPLC). Solid phase extraction was with 
aluminum oxide (Bioanalytical Systems, West Lafayette, IN) and elution was in 0.2 N 
perchloric acid. Dihydroxybenzylamine was used as an internal standard to determine 
extraction efficiency. Electrochemical detection (ESA, Chelmsford, MA) utilized a 150 x 
2 mm C18 (3 µm) Hypersil column (Keystone Scientific, Bellfonte, PA) fitted with a 2 
mm C18 (3 µm) Hypersil javelin guard column (Keystone Scientific). Mobile phase (pH 
= 3.0) was 75 mM NaH2PO4, 1.7 mM 1-ocatanesulfonic acid, 25 µM Na2EDTA, 7% 
(vol/vol) acetonitrile and 0.1% (vol/vol) triethylamine. The interassay coefficient of 
variation was less than 3%.  
 
Statistical Analysis 
 Data are presented as mean ± SEM and were analyzed by one- or two-way 
ANOVA depending on the experimental design with repeated measurements in the time 
factor as applicable. Post hoc comparisons of individual group means were carried out 




Blood glucose changes  
Table 4.1 demonstrates that when C57BL/6J mice were food deprived for 12 h, 
blood glucose ranged from 99 ± 4 to 103 ± 3 mg/dl. When mice were injected IP with 
insulin, blood glucose fell. Blood glucose 0.75h after 0.8 units/kg of insulin was 50 ± 2 
mg/dl (p < 0.001) compared to control (105 ± 4 mg/dl). Food was made accessible to the 
mice 0.75h post-injection. At 2h post-insulin injection and 1.25h after a return to 
unrestricted food access, blood glucose ranged from 172 ± 5 to 166 ± 4 mg/dl in control 
and insulin-treated animals. Blood glucose normalized to 150 ± 10 and 148 ± 10 mg/dl in 
control and insulin-treated animals by 4h post- injection, and 3.25h after a return to 
unrestricted food access. 
 
Insulin-induced hypoglycemia is associated with depressive-like behavior and 
anhedonia. 
Fig. 4.1 shows the impact of insulin administration on mobility. The total number 
of crossings (Fig. 4.1A) 24h after 0.8 units/kg of insulin (80 ± 7) was not significantly 
different from that of control mice (78 ± 9) and the total distance moved (Fig. 4.1B) 24h 
after 0.8 units/kg of insulin (1533 ± 60 cm) was also not significantly different from that 
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of saline-treated mice (1677 ± 141 cm).  
To test whether acute insulin induces depressive-like behavior, the FST and TST 
were conducted. In animal models, FST and TST are the most commonly used tools for 
screening depressive-like behaviors (Dantzer et al., 2008; Dantzer, 2009; Petit-
Demouliere et al., 2005; Steru et al., 1985). As shown in Fig. 4.2A, immobility during 
FST was increased 24h after acute IP insulin treatment, 138 ± 9 seconds compared to 99 
± 6 seconds (p=0.004). Recovery from insulin-induced increased immobility in FST took 
48 h. However, acute insulin treatment did not significantly affect behavior in the TST.  
Finally, a saccharin preference test was conducted to assess hedonic tone. 
Depressed mice are reported to show a decreased preference for sweet solutions (Dantzer 
et al., 2008; Dantzer, 2009). As shown Fig. 4.3, insulin-treated mice showed a decrease 
in saccharin preference within 24h after insulin injection. These findings indicate that 
insulin-induced hypoglycemia is associated with depressive-like behavior and anhedonia, 
but not mobility. 
To investigate a function of hippocampal-dependent working memory (Sutcliffe 
et al., 2007), anxiety (Shepherd et al., 1994) and behavioral dysfunction (Deacon, 2006), 
a novel object recognition test (Fig. 4.9A), elevated zero maze (Fig. 4.9B) and a 
burrowing test (Fig. 4.9C) were conducted. However, behaviors in these tests were not 
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significantly affected by acute insulin treatment. 
 
Increased immobility in FST is improved by antidepressant treatment.  
Most antidepressant medications work by increasing the levels of one or more of 
the monoamines such as dopamine, serotonin or norepinephrine in the synaptic cleft 
between neurons. To ensure that increased immobility in the FST is directly associated 
with depressive-like behavior (Dantzer et al., 2008), antidepressants were given with or 
without insulin 0.5h prior to the FST. Two different antidepressants were used: a 
norepinephrine and serotonin reuptake inhibitor (desipramine), and a selective serotonin 
reuptake inhibitor (fluoxetine, = Prozac). As shown in Fig. 4.4, increased immobility in 
FST was improved by both antidepressant treatments, indicating insulin-induced 
hypoglycemia is associated with depressive-like behavior. 
 
Hypoglycemia increased plasma catecholamines and corticosterone. 
 Fig. 4.5A demonstrates that 0.8 units/kg insulin IP induced a marked elevation in 
plasma Epi and NE. At 0.75h after insulin, Epi was increased compared to control, 921 ± 
256 pg/ml vs 350 ± 40 pg/ml (p = 0.044). At 72h after insulin, Epi returned to near 
control levels, 738 ± 343 pg/ml vs 350 ± 40 pg/ml (p = 0.242). After insulin (0.75 h), NE 
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increased to 787 ± 311 pg/ml vs 265 ± 28 pg/ml (p = 0.102) and was elevated at 24h 
post-insulin, 541 ± 155 pg/ml vs 265 ± 28 pg/ml (p = 0.08).  
 Fig. 4.5B indicates that 0.8 units/kg insulin IP induced a marked elevation in 
plasma corticosterone. At 0.75h after insulin, corticosterone showed a non-significant 
increase (p = 0.87) compared to control, 163 ± 38 ng/ml vs 80 ± 14 ng/ml. At 24h after 
insulin, plasma corticosterone levels were significantly higher, 325 ± 23 ng/ml vs 119 ± 
32 ng/ml (p = 0.02). 
 
Exogenous catecholamines cause depressive-like behavior. 
 To establish if increased catecholamines mediate behavioral changes, we treated 
mice with Epi and NE and FST was measured. Fig. 4.5C shows the impact of insulin 
administration on mobility. Epi and NE did not influence the total distance moved at 24h 
post-IP injection, as measured by Noldus EthoVision. Two hour data used for a negative 
control indicated that Epi and NE induced loss of activity, as shown in a previous study 
(Park et al., 2008). Fig. 4.5D shows that when Epi was administered IP at 1.5 mg/kg, 
immobility during FST was significantly increased 24h after injection (108 ± 13 vs. 
control 71 ± 5, p = 0.0221). FST immobility was also increased at 24h when NE was 
administered IP at 1.5 mg/kg (127 ± 13 vs. 71 ± 5, p=0.0034) and rectified at 48h (p=0.7). 
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Taken together, these findings indicate that catecholamines increase immobility in FST. 
 
Does β-2 adrenergic receptor antagonism prevent insulin-induced depressive-like 
behavior? 
Decreased β-2 AR densities seem to be associated with hypoglycemia incidence 
(blood glucose < 50 mg/dl) and symptomatic hypoglycemia unawareness (Schwab et al., 
1993; Schwab et al., 2004), and expression of β-2 AR mRNA appears inversely tied to 
life stress (Miller and Chen, 2006). To determine if catecholamine-dependent depressive-
like behavior is mediated by the AR, α, β-1 and β-2 antagonism were performed using 
Phentolamine (1 mg/kg, pan-α blocker), Metoprolol (10 mg/kg, β-1 blocker) or 
butoxamine (5.0 mg/kg, β-2 blocker). Agonists were pretreated 30 min prior to insulin 
(0.8 units/kg, IP), Epi or NE injection, and 30 min prior to FST test. As shown in Fig. 4.6, 




 We have previously shown that hypoglycemia/hyperinsulinemia induces social 
withdrawal and reduces mouse movement that peaks 0.5 to 2h later and gradually wanes. 
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We also reported that a single dose of insulin was significant enough to increase plasma 
norepinephrine and epinephrine levels, which might be responsible for the social 
withdrawal observed in insulin-induced hypoglycemia. This phenomenon could be 
expected because a low blood glucose level triggers a variety of counter-regulation 
components including catecholamines, glucagon, growth hormone and cortisol. In 
addition, the insulin-induced social withdrawal was reversed by β-2 adrenergic receptor 
blockade (Park et al., 2008). While these data show the early responses to hypoglycemia, 
the current study focused on the later responses. 
Dantzer et al. (2008) reported that peripheral administration of lipopolysaccharide 
(LPS) induced sickness behavior that peaked between 2-6h then gradually diminished, 
and depression-like behavior followed sickness behavior 24h later. Using an animal 
model of cytokine-induced depression, they reviewed similarities between sickness 
behaviors and depression-like behaviors (Dantzer et al., 2008). For instance, the decrease 
in motor activity presented by sick animals is similar to the increased immobility during 
FST. In the same way, the reduced appetite of sick individuals translates into a decreased 
intake of rewarding aliments, mimicking depression-associated anhedonia. They also 
suggested using pharmacological validation by antidepressant treatment to confirm 
depressive-like behavior. Here we show that insulin induced depressive-like behavior 
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and anhedonia, as measured by increased immobility during FST (Fig. 4.2A), and 
decreased preference for a sweet solution (Fig. 4.3) 24 hours post-injection. The 
increased immobility during FST and decreased intake of sweet solution (behavioral 
validation) were abolished by antidepressant treatment (pharmacological validation) (Fig. 
4.4).  
An important question arises when considering the insulin-induced increase in 
immobility during FST. Is it insulin itself or the insulin-induced glucose deficit that is 
causing this depressive-like behavior? As shown in Table 4.2 and Fig. 4.7, ICV insulin 
administration neither decreased blood glucose nor increased immobility during FST. 
More interestingly, as shown in Table 4.3 and Fig. 4.8, insulin did not increase 
immobility during FST when mice did not reach a hypoglycemic state. These findings 
strongly support our contention that depression-like behavior is associated with an 
insulin-induced glucose deficit, but not with insulin per se.  
More direct evidence for catecholamine involvement in mood changes comes 
from a study of adrenalectomized patients (Hepburn et al., 1996). While normal 
individuals showed increased plasma adrenalin and tense arousal and a decrease in 
hedonic tome in response to acute insulin-induced hypoglycemia, adrenalectomized 
patients (as treatment for Cushing’s disease) neither secreted adrenaline nor exhibited 
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tense arousal and changes in hedonic tone under the same condition (Hepburn et al., 
1996).  These observations suggest that the marked increase in adrenaline secretion 
from the adrenal medulla plays a critical role in the generation of changes in tense 
arousal and hedonic tome (Hepburn et al., 1996). In a study of healthy participants, Gold 
et al. (Gold et al., 1995) reported mood changes induced during insulin-induced 
hypoglycemia. The acute hypoglycemia caused negative mood states including a 
reduction in hedonic tone, an increase in tense arousal and a decrease in energetic arousal. 
McCrimmon et al. (1995) also reported that 16 healthy individuals exposed to insulin-
induced hypoglycemia presented increased anger and became more pessimistic about 
their life problems in addition to a reduction in hedonic tone and an increase in tense 
arousal (McCrimmon et al., 1995). Hislop et al. (2008) reported approximately one-third 
of young adults with T1D experience psychological distress, which is associated with 
poorer glycaemic control (Hislop et al., 2008). These findings of hypoglycemia-induced 
negative changes in mood including diminished energetic arousal, decreased happiness 
and increased anxiety in humans, support our result in mice that insulin-induced 
hypoglycemia caused depressive-like behavior and anhedonia and suggest that 
circulating plasma catecholamines may be important in mediating such changes (Gold et 
al., 1997). Therefore, our experimental model of acute hypoglycemia is a useful method 
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for studying mood in humans and animals (Gold et al., 1995).  
Fig. 4.5D demonstrates that peripheral administration of Epi/NE caused increased 
immobility during FST. These findings indicate that Epi or NE might be responsible for 
the depression-like behavior seen with insulin-induced hypoglycemia. In a review of the 
roles of catecholamines in depression, Potter (1994) and many other findings showed 
that patients with major depression presented some degree of increased plasma NE levels, 
indicating increased peripheral sympathetic nervous system activity in depressed 
individuals (Barnes et al., 1983; de Villiers et al., 1987; Lake et al., 1982; Roy et al., 
1985; Roy et al., 1987; Rudorfer et al., 1985; Wyatt et al., 1971). More specifically, 
enhanced levels of plasma NE were found in patients with depression (de Villiers et al., 
1987; Rudorfer et al., 1985), anxiety (Wyatt et al., 1971), major affective disorder (Lake 
et al., 1982) and/or melancholia (Roy et al., 1985). Fig. 4.6 shows that the α, β 1 and β 2 
adrenergic receptor blockade reversed hypoglycemia-associated increases in forced swim 
immobility without raising blood glucose in response to insulin, indicating that insulin-
induced depression-like behavior is not directly mediated by hypoglycemia but by the 
impact hypoglycemia has on catecholamines via an adrenergic receptor-mediated 
pathway. There are various studies concerning the effects of α and β adrenergic receptor 
agonists and/or antagonists on biochemical, neuroendocrine or behavioral system. 
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Studies using α 2 adrenergic receptor agonists (e.g. clonidine or UK-14304) 
demonstrated an increased maximum binding in platelets of depressed patients (Garcia-
Sevilla et al., 1986; Garcia-Sevilla et al., 1990; Pandey et al., 1989; Piletz et al., 1986), 
providing evidence for an α 2 hypersensitivity theory of depression (Potter and Manji, 
1994). Others reported the opposite, showing α 2 inhibition of platelet adenylate cyclase 
activity suggestive of subsensitive α 2 adrenergic receptors in depression (Kafka and 
Paul, 1986; Pandey et al., 1990). In addition, the reduction in β adrenergic receptors and 
sensitivity of β adrenergic receptor-stimulated adenylate cyclase found in rodent brain 
after chronic administration of all classes of antidepressant treatment indicate that such 
alterations may be associated with the therapeutic action of antidepressant drugs 
(Banerjee et al., 1977; Potter and Manji, 1994; Sulser et al., 1978). Increases in 
circulating catecholamines and glucocorticoids may play an important role in β 
adrenergic receptor sensitivity (Werstiuk et al., 1990), possibly via their effects on the 
stimulatory G protein (Gs) (Malbon, 1989; Potter and Manji, 1994). Since the roles of α 
and β adrenergic receptors in mood disturbances are still controversial across the 
literature, additional studies are crucial to further our understanding their roles.  
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4.6 Figures and Tables 





0h 0.75h 2h 4h 24h 
Saline 152 ± 6 99 ± 4 105 ± 4 172 ± 5 150 ± 10 152 ± 7
Insulin (0.8 units/kg) 149 ± 6 103 ± 3 50 ± 2* 166 ± 4 148 ± 10 145 ± 8











(B) Distance moved (cm) 
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Fig. 4.1, continued 
Fig. 4.1. Insulin administration does not impact mobility. After a 12h fast, C57BL/6J 
mice were administered either insulin or saline control IP as indicated. Locomotor 
activity was measured at 0, 4 and/or 24h after insulin delivery. Unrestricted access to 
food was provided within 30 min post-injection. Results are expressed as total line 
crossings (A) or distance moved as measured by computer program, Noldus (B), means 










(B) Tail suspension test immobility (seconds/10 min) 
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Fig. 4.2, continued 
Fig. 4.2. Insulin administration increases FST immobility, but not TST immobility. 
After a 12h fast, C57BL/6J mice were administered either insulin or saline control IP as 
indicated. Forced swim test and tail suspension test were measured at 24, 48 and/or 72h 
after insulin delivery. Unrestricted access to food was provided within 45 minutes post- 
injection. Results are expressed as immobility in the FST (A) or that of TST (B), means ± 


































Fig. 4.3. Insulin-treated mice showed a decrease in saccharin preference. After a 12h 
fast, C57BL/6J mice were administered either insulin or saline control IP as indicated. 
Saccharin preference test was measured at 24 and 48h post-insulin administration. 
Unrestricted access to food was provided within 45 minutes post-injection. Results are 
expressed as Saccharin preference (%) = {Saccharin consumption / (water consumption 









Fig. 4.4. Increased immobility in FST is improved by antidepressant treatment. 
After a 12h fast, C57BL/6J mice were administered either insulin or saline control IP as 
indicated. 0.5h prior to FST, mice were given saline, fluoxetine or desipramine. Results 
are expressed as immobility in the FST, means ± SEM; n=9; p<0.05. 

































































Fig. 4.5. Hypoglycemia causes an increase in plasma catecholamines and 
corticosterone, and exogenous catecholamines increase immobility in FST. (A) and 
(B) After a 12h fast, C57BL/6J mice were administered either insulin or saline control at 
0.8 units/kg insulin IP as indicated. Plasma catecholamines and corticosterone were 
measured by HPLC at 0, 0.75 and 24h post-insulin injection. Results are expressed as 
mean ± SEM; n = 4, *P <0.05, Insulin vs. Saline. (D) Mice were administered Epi (IP) or 
NE (IP) at the concentrations indicated. FST was measured at 24 and 48h after Epi or NE 
delivery. means ± SEM; n=4, *P<0.05, Epi or NE vs. Saline at 24 h. 
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Figure 4.6  
 
Fig. 4.6. Hypoglycemia-induced increased immobility in FST is improved by AR 
blockers treatment. (A) After a 12h fast, C57BL/6J mice were pretreated with or 
without phentolamine (Phen) (1 mg/kg, IP), metoprolol (Meto) (10 mg/kg, IP) or 
butoxamine (BTX) (5 mg/kg, IP) as indicated. Mice were then administered insulin (Ins) 
(0.8 units/kg) IP or saline control (Saline) IP as indicated. FST was measured at 24h after 
insulin delivery. Results are expressed as seconds/5 min of immobility in FST, means ± 
SEM; n=9; p<0.05. 
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0h 0.75h 2h 4h 24h 
Saline, ICV 161 ± 13 114 ± 3 116 ± 8 132 ± 5 131 ± 13 142 ± 13 
Insulin, ICV  156 ± 9 108 ± 6 113 ± 9 141 ± 13 136 ± 7 151 ± 14 





Fig. 4.7. Forced swim test immobility (seconds/5min) post insulin ICV (0.2 
units/mouse/2 µl) administration. After a 12h fast, C57BL/6J mice were administered 
either insulin ICV (0.2 units/mouse/2 µl) or saline ICV as indicated. FST was measured 
at 24 and 48h after insulin delivery. Unrestricted access to food was provided within 45 
minutes post-injection. Results are expressed as immobility in the FST, means ± SEM; 
n=3-4. 
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Table 4.3: Blood Glucose (mg/dl) after Insulin IP Injection (without fasting) 
 
 0 min 10 min 20 min 40 min 60 min 80 min 
Saline 141 ± 6 152 ± 12 167 ± 7 177 ± 7 172 ± 3 166 ± 5 
Insulin 131 ± 15 99 ± 11 101 ± 6 122 ± 1 168 ± 10 172 ± 10 







Fig. 4.8. Forced swim test immobility (seconds/5 min) post-insulin IP injection 
(without fasting). C57BL/6J mice were administered either insulin or saline IP as 
indicated. FST was measured at 24h after insulin delivery. Results are expressed as 

















Fig. 4.9. Novel object recognition test, elevated zero maze and burrowing test post-
insulin IP injection. C57BL/6J mice were administered either insulin or saline IP as 
indicated and novel object recognition, elevated zero maze and burrowing test were 
measured at indicated time points. Means ± SEM; n=4 (A). n=7-9 (B), n=12-14 (C). 
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CHAPTER 5: OVERALL SUMMARY AND FUTURE DIRECTIONS 
The overall objective of this work was to investigate the possible mechanisms of 
behavior and mood changes induced by hypoglycemia/hyperinsulinemia. Our first 
objective was to determine how insulin-induced hypoglycemia causes social withdrawal 
and if intervention with adrenergic receptor antagonists could speed recovery from social 
withdrawal. Here we show that hypoglycemia/hyperinsulinemia decreased mouse 
movement and induced a reduction in social exploration that peaked 0.5-2h later, and 
then gradually waned. The dose of insulin administered (0.8 units/kg) was significant 
enough to increase plasma NE and Epi levels, which might be responsible for the social 
withdrawal observed in insulin-induced hypoglycemia. Importantly, insulin-induced 




The second objective of this dissertation was to investigate how insulin-induced 
hypoglycemia causes depressive-like behavior and anhedonia. To answer this question, 
we were interested in determining if an increase in catecholamines mediates depressive-
like bahavior in insulin-induced hypoglycemia and if adrenergic receptors are associated 
with depressive-like behavior and anhedonia. We found that insulin induced saccharin 
aversion and increased immobility during FST in mice. Importantly, blocking adrenergic 
receptors or treatment with anti-depressants abolished both these behaviors. Therefore, 
the data suggest that hypoglycemia-induced anhedonia and depressive-like behavior are 





As described above, we have shown that insulin-induced social withdrawal and 
depressive-like behavior are associated with catecholamines and can be reversed by 
adrenergic receptor blockade. In addition to catecholamines, other studies have shown a 
relationship between behavioral/mood change and corticotropin-releasing hormone 
(CRH). CRH is one of the hormones involved in the HPA-axis and is produced by 
parvocellular neuroendocrine cells of the hypothalamus. CHR is released into the 
anterior lobe of the pituitary, where it stimulates corticotropes to secrete corticotropin 
(adrenocorticotropic hormone, ACTH). CRH has been reported to induce behavioral 
activation including an increase in grooming and freezing behavior, and a decrease in the 
number of approaches to a food pellet in a rat model (Sutton et al., 1982). Moreover, it 
has been shown that CRH is anxiogenic in that it suppresses social interaction and 
potentiates acoustic startle in animal models (Dunn and File, 1987). Holsboer reviewed 
and reported a potential role for CRH receptor antagonist to treat depression and anxiety 
(Holsboer, 1999). Most of the behavioral and mood changes induced by CRH were 
blocked by α-helical CRH9–41, which acts as a CRH receptor antagonist. This α -helical 
CRH9-41 has been reported to suppress the rise of plasma epinephrine after insulin-
induced hypoglycemia (Jacobson et al., 2006). Since Epi secretion from the adrenal 
medulla plays a critical role in the generation of changes in tense arousal and hedonic 
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tone, further experiments using CRH-KO mice and/or α -helical CRH9-41 may show 
clearer support for our hypothesis that catecholamines and corticosterone play a critical 
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